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ABSTRACT 
Sarah Cassidy Nabinger 
 
MOLECULAR MECHANISMS OF  
FLT3-ITD-INDUCED LEUKEMOGENEISIS 
 
Internal tandem duplications in FMS-like receptor tyrosine kinase (FLT3-ITDs) 
are seen in approximately 25% of all acute myeloid leukemia (AML) patients.  FLT3-
ITDs induce FLT3 ligand (FL)-independent cellular hyperproliferation, promiscuous and 
aberrant activation of STAT5, and confer a poor prognosis in patients; however, the 
molecular mechanisms contributing to FLT3-ITD-induced malignancy remain largely 
unknown.   
The protein tyrosine phosphatase, Shp2, is important for normal hematopoiesis as 
well as hematopoietic stem cell (HSC) differentiation, engraftment, and self-renewal.  
Furthermore, FLT3-ITD- or constitutive active STAT5-expressing CD34+ cells 
demonstrate enhanced hematopoietic stem cell self-renewal.  Together with the previous 
findings that Shp2 is critical for normal hematopoiesis, that dysregulated Shp2 function 
contributes to myeloid malignancies, and that Shp2 has been shown to interact with WT-
FLT3 tyrosine 599, which is commonly duplicated in FLT3-ITDs, a positive role for 
Shp2 in FLT3-ITD-induced signaling and leukemogenesis is implied.   
I demonstrated that Shp2 is constitutively associated with the reported FLT3-
ITDs, N51-FLT3 and N73-FLT3, compared to WT-FLT3; therefore, I hypothesized that 
increased Shp2 recruitment to N51-FLT3 or N73-FLT3 contributes to hyperproliferation 
vi 
 
and hyperactivation of STAT5.  I also hypothesized that Shp2 cooperates with STAT5 to 
activate STAT5 transcriptional targets contributing to the up-regulation of pro-leukemic 
proteins.  Finally, I hypothesized that reduction of Shp2 would result in diminished N51-
FLT3-induced hyperproliferation and activation of STAT5 in vitro, and prevent FLT3-
ITD-induced malignancy in vivo.  I found that genetic disruption of Ptpn11, the gene 
encoding Shp2, or pharmacologic inhibition of Shp2 with the novel Shp2 inhibitor, II-
B08, resulted in significantly reduced FLT3-ITD-induced hematopoietic cell 
hyperproliferation and STAT5 hyperphosphorylation.  I also demonstrated a novel role of 
Shp2 in the nucleus of FLT3-ITD-expressing hematopoietic cells where Shp2 and 
STAT5 co-localized at the promoter region of STAT5-transcriptional target and pro-
survival protein, Bcl-XL.  Furthermore, using a Shp2flox/flox;Mx1Cre+ mouse model, I 
demonstrated that reduced Shp2 expression in hematopoietic cells resulted in an 
increased latency to and reduced severity of FLT3-ITD-induced malignancy.  
Collectively, these findings demonstrate that Shp2 plays an integral role in FLT3-ITD-
induced malignancy and suggest that targeting Shp2 may be a future therapeutic option 
for treating FLT3-ITD-positive AML patients.    
 
     
 Rebecca J. Chan, MD/PhD, Chair 
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CHAPTER ONE 
INTRODUCTION 
 
Acute Myeloid Leukemia 
Acute myeloid leukemia (AML) is a disease predominantly affecting older 
individuals and accounts for about 25% of all leukemias in adults in the western world 
(Deschler and Lubbert 2006; Estey and Dohner 2006).  Patients with AML often present 
with an overabundance of myeloid cells, anemia, and thrombocytopenia.  Generally, 
afflicted individuals may be overly tired, have an increase in bruising or bleeding, 
recurrent fever, infections, or unexplained weight loss.  In the recent past, the incidence 
of patients over 65 with AML was over 9 times higher than that of patients under 65 
years old (Deschler and Lubbert 2006) (Figure 1.1).  Furthermore, patients under 65 years 
old had a 34.4% 5-year survival rate, while patients over 65 years old, had a dismal 
survival rate of merely 4.3% (Deschler and Lubbert 2006) (Figure 1.2).  As the mean age 
of the population continues to increase, there is a growing population of older 
individuals, making better treatments and curative therapies for AML urgently needed.  It 
is extremely important to recognize the difficulty in treating older patients with AML.  
As patients age, they tend to develop multiple co-morbidities and, thus, become less 
tolerant of harsh chemotherapy and radiation (Deschler and Lubbert 2006; Estey and 
Dohner 2006; Melchert 2006).  Because of these complications, older patients are often 
ineligible for cytotoxic therapy and are only treated with supportive, rather than curative, 
care.  Therefore, it is imperative that therapies with reduced toxicity and increased 
efficacy are developed to treat AML patients.  
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Figure 1.1:  AML is predominantly diagnosed in aging individuals 
 
Incidence of AML diagnosis represented as the number of people diagnosed with AML 
out of 100,000.  Figure is adapted from Deschler et al. (Deschler and Lubbert 2006).   
 
 
Figure 1.2:  5-year survival rate of AML patients by age group 
 
The 5-year survival rate of AML patients is divided into 3 age groups: under 45 (<45), 
under 65 (<65), and over 65 (65+) years old and is displayed as percent survival.  Figure 
adapted from Deschler et al. (Deschler and Lubbert 2006).   
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AML and FLT3 Mutations   
Internal tandem duplications in FMS-like tyrosine kinase (FLT3-ITD) are 
insertions of several amino acids into or around the juxtamembrane domain and are 
present in approximately 25% of all AML patients (Kelly, Liu et al. 2002; Georgiou, 
Karali et al. 2006; Heiss, Masson et al. 2006; Rocnik, Okabe et al. 2006; Small 2006).  
The WT-FLT3 amino acid sequence of the juxtamembrane domain is shown in figure 1.3 
with several examples of FLT3-ITDs, their specific duplications, and insertion sites into 
the juxtamembrane domain.  It is well-known that these FLT3-ITDs contribute to a poor 
prognosis.  Figure 1.4 displays a Kaplan Meijer curve from a study by Abu-Duhier and 
colleagues comparing the FLT3-ITD status of AML patients (FLT3-ITD-positive or 
negative) with survival (Abu-Duhier, Goodeve et al. 2000).  There was an obvious 
decrease in the survival of patients that were FLT3-ITD+ compared to AML patients that 
were FLT3-ITD- with a p-value of 0.0002.    
FLT3-ITD mutations result in constitutive FLT3 phosphorylation, FLT3 ligand 
(FL)-independent cellular hyperproliferation, and aberrant activation of signal transducer 
and activator of transcription 5, STAT5 (Mizuki, Schwable et al. 2003; Chung, Morrone 
et al. 2005; Kato, Iwama et al. 2005; Rocnik, Okabe et al. 2006; Choudhary, Brandts et 
al. 2007).  STAT5 is a transcription factor which is known to activate pro-cycling 
molecules such as Cyclin D1 (Joung, Lim et al. 2005) and anti-apoptotic proteins such as 
Bcl-XL (Beverly and Varmus 2009; Mizukawa, Wei et al. 2011).  We wish to investigate 
the molecular mechanism(s) underlying the transforming capacity of FLT3-ITDs in an 
effort to develop novel, molecularly-targeted, and less toxic therapies for individuals with 
FLT3-ITD-positive AML.   
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Figure 1.3:  Examples of FLT3-ITDs 
 
The WT-FLT3 receptor is shown in the schematic with listing the amino acid sequence of 
the jutamembrane domain highlighting the different tyrosine residues.  Below the WT-
FLT3 sequence are the amino acid sequences and where they are inserted of several 
reported FLT3-ITDs.  We will frequently use the FLT3-ITD, N51-FLT3. 
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Figure 1.4:  Cumulative Survival of FLT3-ITD-negative (-) vs. FLT3-ITD-positive 
(+) patients   
 
Data is presented as cumulative survival of AML patients that are either FLT3-ITD+ or 
FLT3-ITD-.  P-value derived from log-rank test; figure adapted from Abu-Duhier et al., 
Br. J. Haematol., 2000. 
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Wildtype FLT3   
To better understand the potential signaling aberrations of the FLT3-ITDs, we 
will first explore data presented on wildtype (WT) FLT3.  FMS-like tyrosine kinase 3, 
FLT3, is a member of the class III receptor tyrosine kinase family which also includes 
platelet-derived growth factor receptor (PDGFR) and stem cell growth factor receptor, c-
Kit.  FLT3 is normally expressed on immature hematopoietic progenitor cells and 
contributes to proliferation, survival, and differentiation.  Upon stimulation with FLT3 
ligand (FL), FLT3 forms a homodimer and autophosphorylates itself resulting in the 
activation of downstream signaling cascades. 
 
Wildtype FLT3 Recruits the Protein Tyrosine Phosphatase, Shp2 
To better understand the molecular mechanism of normal FLT3 function, Heiss et 
al. investigated the wildtype (WT) FLT3 receptor.  They determined that activated WT-
FLT3 recruits the protein tyrosine phosphatase, Shp2, via autophosphorylation of tyrosine 
599 (Y599) in the juxtamembrane domain (Heiss, Masson et al. 2006).  To do this, the 
autophosphorylation sites in the juxtamembrane domain of WT-FLT3 were mapped, 
identifying tyrosines 572, 589, 591, and 599 as sites of autophosphorylation in vivo.  
Next, tyrosine (Y) residues were mutated to phenylalanine (F) and WT-FLT3, FLT3-
Y589F and FLT3-Y599F constructs were stably transduced into 32D cells.  Upon 
examination of FLT3 ligand (FL)-induced responses, it was determined that Y589F and 
Y599F exhibited distinct FL-dependent phenotypes.  Stimulation of WT-FLT3 induced 
Erk activation which remained high in cells expressing the Y589F construct; however in 
cells expressing the Y599F construct, Erk activation was diminished.  This suggested that 
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phosphorylation of Y599 specifically contributes to Erk activation.  Next, the authors 
determined that Shp2 directly associates with pY599 in biochemical experiments.  
Protein extracts from 32D-WT-FLT3 and 32D-FLT3-Y599F cells were prepared and 
incubated with glutathione S-transferase (GST)-conjugated Shp2.  These proteins were 
separated on SDS-PAGE, transferred to nitrocellulose membrane, and probed for FLT3.  
These studies demonstrated that Shp2 was recruited to WT-FLT3 but not FLT3-Y599F.  
This further strengthened their argument that Shp2 associates with Y599 in the 
juxtamembrane domain of FLT3.  Finally, they measured cell growth by MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assays to demonstrate that FL 
stimulation results in increased cell numbers in WT-FLT3 32D cells.  However, FL 
stimulation of 32D-FLT3-Y599F cells did not induce cell growth.   
Thus, these studies suggest that in WT-FLT3 receptor signaling, Shp2 binds Y599 
and this interaction is required for Erk activation and normal FL-stimulated cell growth 
(Heiss, Masson et al. 2006).  Interestingly, Y599 is conserved in all members of the class 
III receptor tyrosine kinase family, and mutation of tyrosine 577 (Y577) in PDGFR (the 
tyrosine homologous to Y599), leads to constitutive receptor tyrosine phosphorylation 
and ligand-independent cellular proliferation (Irusta, Luo et al. 2002).  These findings 
suggest that Y599 in FLT3 may be important in FL-independent growth and when 
duplicated in FLT3-ITDs, may contribute to FLT3-ITD-induced leukemogenesis. 
 
Protein Tyrosine Phosphatase Shp2 
Shp2 is a ubiquitously expressed cytosolic signaling molecule encoded by the 
gene Ptpn11.  It has two Src homology 2 (SH2) domains (N-terminal and C-terminal) 
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Figure 1.5:  Schematic representation  
of Shp2 activation (adapted from  
(Chen, Sung et al. 2006)) 
located in the amino end and a phosphatase domain localized to the carboxyl terminus 
(Figure 1.5).  Shp2 is important in a wide variety of cell processes including cell 
proliferation, differentiation, cell cycle maintenance, and migration. One simplistic 
schematic of Shp2 activation is shown in Figure 1.5.  Upon Shp2 activation, Ras is 
activated which leads to the downstream activation of signaling molecules Raf and Mek 
which ultimately activates mitogen-activated protein kinase, MAPK also known as Erk 
(Figure 1.5).   
Approximately 50% of individuals with the congenital disorder, Noonan 
syndrome (NS), bear germline gain-of-function mutations in PTPN11, and NS patients 
have an increased incidence of juvenile myelomonocytic leukemia (JMML).  Somatic 
gain-of-function mutations in Shp2 have also been associated with other malignancies in 
addition to myeloid leukemia (Tartaglia, Niemeyer et al. 2003; Bentires-Alj, Gil et al. 
2006), and wildtype Shp2 has been 
shown to be over-expressed in several 
human AML cases (Xu, Yu et al. 2005).  
These data demonstrate that Shp2 is 
implicated in human diseases and 
leukemogenesis.  Given that leukemia 
is a proliferative disease of the stem and 
hematopoietic progenitor cells, we next 
investigated the known functions of 
Shp2 in normal stem cell function and 
hematopoiesis.    
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Shp2 in Normal Hematopoiesis and in Hematopoietic Stem Cell Function   
Shp2 is an essential, ubiquitously expressed protein tyrosine phosphatase as 
evidenced by the fact that Shp2-/- animals are embryonic lethal (Saxton, Henkemeyer et 
al. 1997).  Using ES cells bearing an exon 3 deletion from Ptpn11 resulting in an in-
frame deletion of amino acids 46-110 within the N-terminal SH2 domain of the mature 
Shp2 protein, Qu et al. demonstrated that embryoid body (EB) differentiation in the form 
of erythroid and myeloid development was impaired compared to WT ES cells (Qu, Shi 
et al. 1997).  They further went on to use Shp2-/- -WT chimeric animals to demonstrate 
that Shp2-/- ES cells failed to contribute to hematopoietic progenitors in fetal liver and 
bone marrow, resulted in deficient yolk sac hematopoiesis, and resulted in multiple 
developmental defects of chimeric animals (Qu, Yu et al. 1998).  Finally, Chan et al. 
demonstrate a role of Shp2 in the initial steps of ES cell differentiation (Chan, Johnson et 
al. 2003) using the previously described truncated-Shp2-bearing ES cells.  Furthermore, 
using haploinsufficient Shp2+/- animals, it was demonstrated that Shp2+/-  bone marrow 
cells have reduced hematopoietic stem cell (HSC) repopulating units and reduced self-
renewal after transplantation into lethally irradiated hosts compared to that of WT bone 
marrow (Chan, Li et al. 2006).  Collectively these data suggest that Shp2 is important in 
normal hematopoiesis by promoting differentiation from very early stages of ES cell 
development and by supporting HSC function and self-renewal. 
As previously mentioned, complete Shp2 knock out is embryonic lethal, 
therefore, Shp2flox/flox animals were designed and studied by Geng-Sheng Feng’s lab 
(Zhang, Chapeau et al. 2004).  Initially they crossed these Shp2flox/flox animals with a 
neuronal-specific Cre to examine the loss of Shp2 in brain tissues.  These Shp2flox/flox 
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animals were later crossed with Mx1Cre+ transgenic animals and used to demonstrate 
that a loss of Shp2 results in cytopenia in peripheral blood, bone marrow, and spleen 
(Zhu, Ji et al. 2011).  They also demonstrated that Shp2 deficient HSCs failed to 
reconstitute lethally irradiated recipients and that this defect is cell-autonomous, 
collectively supporting the importance of Shp2 in self-renewal, homing, and survival 
(Zhu, Ji et al. 2011).  In a similar Shp2-deficient mouse model developed in the Ben Neel 
lab, Mx1Cre+;Ptpn11flox/flox animals also demonstrated that loss of Shp2 results in a rapid 
decrease of HSCs and hematopoietic progenitors from all lineages in a dose-dependent 
and cell autonomous manner (Chan, Cheung et al. 2011).  These complementary studies 
demonstrate that Shp2 is an important factor in normal hematopoiesis contributing to 
self-renewal, maturation, and differentiation of HSC/progenitors.  Given that acute 
leukemia is a disease of dysregulated HSCs and given the importance of Shp2 in HSC 
function, we rationalized that dysregulated Shp2 function in the context of FLT3-ITD+ 
leukemia may promote leukemogenesis by supporting aberrant HSC function.  This 
hypothesis was further supported by previous findings that FLT3-ITDs as well as 
constitutively activated STAT5, the most robust neomorphic signal found in FLT3-ITD+ 
cells, also leads to increased HSC self-renewal. 
 
The Role of STAT5 and FLT3-ITD in Hematopoietic Stem Cell Function 
Moore and colleagues published two important studies examining the function of 
STAT5 and FLT3-ITD using human cord blood CD34+ cells.  CD34+ cells were 
transduced with constitutive active STAT5 and used to demonstrate that CD34+ cells 
expressing active STAT5 have increased self-renewal and contribute to increased 
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proliferation and generation of erythroid progenitors (Schuringa, Chung et al. 2004).  In 
another study, CD34+ cord blood cells were transduced with either WT-FLT3 or N51-
FLT3 and the N51-FLT3-transduced cells had a proliferative advantage and were able to 
generate early cobblestone areas which maintained self-renewal upon plating into 
secondary and tertiary cobblestone area-forming cell (CAFC) assays (Chung, Morrone et 
al. 2005).  Although the authors did not directly examine the molecular mechanisms, 
these data provide evidence that either FLT3-ITD and/or hyperactive STAT5 contribute 
to increased HSC self-renewal.  Given that AML is a clonal disorder of undifferentiated 
myeloid blasts that is maintained and propagated by a small population of leukemic cells 
with stem cell qualities, these findings may at least partially explain why FLT3-ITDs 
(which are associated with constitutive active STAT5) induce such a robust leukemia. 
 
Constitutive Activation of STAT5 in FLT3–ITD Mutants 
The most well know aberration in FLT3-ITDs is the promiscuous activation of 
STAT5, which is only modestly activated in WT-FLT3 signaling; however, the molecular 
mechanism by which STAT5 is robustly activated in the presence of FLT3-ITDs is 
unknown.  There are four tyrosines in the juxtamembrane domain of wild type FLT3 
(Y589, Y591, Y597, and Y599) which are comonly duplicated in FLT3-ITDs such as 
those published examples of FLT3-ITDs illustrated in figure 1.3.  Notice that Y599 is 
very commonly duplicated among the reported FLT3-ITDs (Figure 1.3).   
Multiple studies have demonstrated that FLT3-ITDs induce constitutive activation 
of STAT5 (Kiyoi and Naoe 2002; Mizuki, Schwable et al. 2003; Chung, Morrone et al. 
2005; Kato, Iwama et al. 2005; Rocnik, Okabe et al. 2006; Choudhary, Brandts et al. 
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2007), in contrast to physiologic FLT3 receptor signaling, which only modestly induces 
STAT5 activation (Zhang and Broxmeyer 2000; Chung, Morrone et al. 2005).  Rocnik et 
al. purified histidine-tagged cDNA encoding amino acids 580-993 of wild type FLT3 and 
performed in vitro autophosphorylation reactions. Residues Y591, Y726, Y942, Y955 
and Y969 were phosphorylated, while Y589, Y597, Y599, Y768, Y793, Y865, Y889, 
Y726, and Y955 were not.  To better understand the role of each tyrosine in FLT3-ITD-
induced transformation, Rocnik and coworkers used a specific FLT3-ITD called N51-
FLT3 (Figure 1.3), which contains a duplication of 7 amino acids including Y597 and 
Y599 and modified several of the identified tyrosine residues to phenylalanine.  Using 
WT-FLT3, N51-FLT3, and N51-FLT3-Y589/591F they found that mutations Y589F and 
Y591F together significantly reduced STAT5 activation compared to N51-FLT3 in both 
Baf3 and 32D cells.  Additionally, when they transplanted bone marrow cells transduced 
with the three constructs (WT-FLT3, N51-FLT3, or N51-FLT3-Y589/591F) into mice 
and tracked survival over time, the N51-FLT3 mice acquired myeloproliferative disease 
with a latency of 40-60 days; however, the WT-FLT3 or N51-FLT3-Y589/591-
transplanted mice showed no signs of myeloproliferative disease with follow-up to 240 
days (Rocnik, Okabe et al. 2006).  Therefore, they concluded that Y589 and Y591 are 
responsible for N51-FLT3-induced constitutive STAT5 activation and contribute to the 
transformation capacity of N51-FLT3 in vivo (Rocnik, Okabe et al. 2006). 
   
Tyrosines 589 and 591 are Important for Autoinhibition of FLT3   
Upon examination of the crystal structure of autoinhibited wild type FLT3, 
Griffith and colleagues observed that the juxtamembrane (JM) domain contains two key 
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tyrosines, Y589 and Y591, which are located in the JM-Switch motif and bind another 
segment of the receptor called the C-lobe.  This binding stabilizes the JM domain 
association with the structural elements of the receptor and maintains the kinase in its 
inactive confirmation (Griffith, Black et al. 2004).  When Y589 and Y591 become 
phosphorylated, they are unable to bind the C-lobe and, thus FLT3 undergoes a 
conformational change to its active form (Griffith, Black et al. 2004).  In other words, 
Y589 and Y591 must be phosphorylated for FLT3 to become activated.  Therefore, 
mutations of Y589 and Y591 to phenylalanine, which precludes phosphorylation at these 
site, would clearly permit FLT3-ITD to remain permanently autoinhibited.  
Consequently, it is not unexpected FLT3-ITD-Y589/591F used by Rocnik and colleagues 
prevents receptor phosphorylation, activation, and myeloproliferative disease in vivo 
(Rocnik, Okabe et al. 2006).  Although these studies are informative by demonstrating 
the importance of Y589 and Y591 in maintaining FLT3 in the inactive conformation, 
these studies do not define what signaling molecules may be aberrantly recruited to 
mutant FLT3 or how the aberrantly recruited signaling moleucles may contribute to 
FLT3-ITD-induced transformation and leukemogenesis. 
 
Shp2 Positively Regulates STAT5 
While some studies have demonstrated that Shp2 inactivates STAT5 (Yu, Jin et 
al. 2000; Chen, Wen et al. 2003), other studies have shown that Shp2 plays a positive role 
in STAT5 activation and signaling (Chughtai, Schimchowitsch et al. 2002; Ke, 
Lesperance et al. 2006).  In a conditional mouse model (Shp2flox/flox crossed with MMTV-
Cre transgenic mice), Shp2-/- mammary gland cells exhibited reduced phoshpho-STAT5 
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(P-Stat5) in response to lactation compared to control animals (Ke, Lesperance et al. 
2006).  Immunoprecipitation experiments revealed that upon prolactin stimulation of 
control mice, the prolactin receptor (PRLR) recruits Jak2 and Shp2 to form a complex.  
However, Shp2-deficient mice are unable to form this complex suggesting Shp2 is 
important in the PRLR-Jak2 activation of STAT5 (Ke, Lesperance et al. 2006).  In 
another study, Chughtai and colleagues demonstrated that STAT5 was phosphorylated 
and associated with Shp2 in a dose-dependent manner in either murine mammary 
epithelial (CH11) or human mammary carcinoma (T47D) cell lines in response to 
prolactin (PRL) stimulation (Chughtai, Schimchowitsch et al. 2002).  To understand the 
role of the SH2 domains in Shp2, 293 cells were transiently transfected with plasmids 
encoding the prolactin receptor (PRLR), STAT5, Jak2 and either wild type Shp2 or Shp2 
containing point mutations in the N-terminal SH2 domain (SHP2-R32K) or the C-
terminal SH2 domain (SHP2-R138K).  Total cell lysates were immunoprecipitated with 
α-Shp2 and blotted with α-STAT5 to look for a Shp2-STAT5 association in response to 
PRL.  The association between STAT5 and Shp2-R138K was significantly reduced while 
interaction between STAT5 and Shp2-R32K appeared normal.  Similarly prepared cell 
lysates were analyzed by western blot analysis for phosphorylation of STAT5.  Cells 
overexpressing WT-Shp2 or Shp2-R32K exhibited a strong activation of STAT5 upon 
PRL stimulation; however, this activation was not induced in cells overexpressing Shp2-
R138K. Thus, the C-terminal SH2 domain of Shp2 is required for physical association 
and phosphorylation of STAT5 in response to PRL (Chughtai, Schimchowitsch et al. 
2002).  Further studies demonstrated that Shp2 was found in a nuclear protein complex 
with STAT5 at the STAT5-responsive β-casein promoter.  These studies provide 
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evidence that in mammary epithelial cells Shp2 plays a positive role in STAT5 signaling 
and may do so by promoting STAT5 function in the nucleus.  While robust Shp2 
expression has been detected in the nuclear fraction of human AML samples, its role in 
the nucleus in the setting of AML has never been investigated; therefore, we 
hypothesized that in response to FLT3-ITDs, perhaps Shp2 associates with and activates 
STAT5 to promote pro-leukemogenic STAT5-target genes such as Bcl-XL and Cyclin-D1 
(Figure 1.6). 
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Figure 1.6:  Schematic representation of proposed N51-FLT3 molecular mechanism  
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Summary and Significance  
While FLT3-ITD-positive AML contributes to a poor prognosis in patients, the 
molecular mechanisms contributing to FLT3-ITD-induced leukemogenesis remain 
largely unknown.  Multiple studies have demonstrated that Shp2 functions 
physiologically in FLT3 receptor signaling (Zhang and Broxmeyer 1999; Zhang, Mantel 
et al. 1999; Heiss, Masson et al. 2006).  We provide novel data demonstrating that Shp2 
is constitutively associated with FLT3-ITDs, N51-FLT3 and N73-FLT3, suggesting that 
increased Shp2 function contributes to FLT3-ITD-induced cellular transformation.   
Since Shp2 has been shown to be important in HSC engraftment, self-renewal, 
homing, and maturation (Qu, Shi et al. 1997; Qu, Yu et al. 1998; Chan, Johnson et al. 
2003; Chan, Li et al. 2006; Chan, Cheung et al. 2011), and is increasingly being 
identified as a key transforming molecule in leukemogenesis (Bentires-Alj, Paez et al. 
2004; Chan, Leedy et al. 2005; Mohi, Williams et al. 2005; Schubbert, Lieuw et al. 2005; 
Xu, Yu et al. 2005; Chan and Feng 2007), it has become an attractive potential target in 
anti-leukemia therapies.  Additionally, given that leukemia is a disease caused by 
dysregulated HSC/progenitor function, and that Shp2, FLT3-ITDs, and constitutively 
activated STAT5 have been shown to promote HSC self-renewal, we reasoned that 
dysregulated Shp2, in the context of FLT3-ITD-poisitve AML may induce constitutive 
activation of STAT5 and its subsequent molecular targets.   
 The role of Shp2 in STAT5 activation and hyperactivation in response to WT-
FLT3 and FLT3-ITD receptor stimulation, respectively, is unknown.  In some studies, 
Shp2 has been shown to inactivate STAT5 (Yu, Jin et al. 2000; Chen, Wen et al. 2003).  
However, paradoxically, other studies show that Shp2 positively regulates STAT5 (Ali, 
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Chen et al. 1996; Berchtold, Volarevic et al. 1998; Chughtai, Schimchowitsch et al. 2002; 
Ke, Lesperance et al. 2006).  Thus, the role of Shp2 in STAT5 activation appears to be 
cell type- and pathway-dependent. Importantly, IL-3- and GM-CSF-stimulation of 
myeloid cells bearing leukemia-associated Shp2 gain-of-function mutations induces 
hyperactivation of STAT5 (Mohi, Williams et al. 2005), suggesting that Shp2 plays a 
positive role in STAT5 activation in the setting of leukemogenesis. 
Our main goal is to better understand these molecular mechanisms contributing to 
FLT3-ITD-positive leukemogenesis in order to determine molecular targets and/or 
molecular-based therapeutic options to treat FLT3-ITD+ AML patients.  Our studies 
specifically address the following hypotheses: 
1. Increased recruitment of Shp2 to N51-FLT3 and N73-FLT3 contributes to 
ligand-independent cellular proliferation and the constitutive STAT5 
activation. 
2. Shp2 forms a complex with STAT5 in the nucleus of FLT3-ITD-bearing 
hematopoietic cells to activate STAT5 transcriptional targets contributing to 
pro-leukemic functions.   
3. Genetic loss of Shp2 results in reduced cellular hyperproliferation and reduced 
activation of STAT5, and consequently prevents FLT3-ITD-induced 
myeloproliferative disease (MPD) or increases the latency to disease onset in 
vivo.  
4. Pharmacologic inhibition of Shp2 results in decreased hyperproliferation and 
hyperactivation of STAT5, and prevents FLT3-ITD-induced malignancy in 
vivo.  
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Overall, our hypothesis is generalized by the schematic diagram in Figure 1.6.  
Duplication of Shp2 binding residue, Y599, in FLT3-ITDs contributes to increased 
recruitment of Shp2 to the mutant receptor and this increased Shp2 recruitment 
contributes to aberrant activation of STAT5.  Subsequently, Shp2 cooperates with 
STAT5 in the nucleus to activate STAT5 target genes and promote hyperproliferation and 
leukemic signals.   
In addressing these hypotheses, we have used functional analyses to determine the 
proliferative potential of FLT3-ITD-bearing cell lines and primary cells compared to 
WT-FLT3-expressing cells.  We also used functional assays to examine FLT3-ITD-
induced hyperproliferation after targeting Shp2 by either shRNAs targeting Shp2, genetic 
disruption of Shp2, or blocking the phosphatase activity of Shp2 by treatment with the 
pharmacologic inhibitor, II-B08. 
To determine the consequences of loss of Shp2 biochemically, 
immunoprecipitation assays were used to demonstrate an increased recruitment of Shp2 
to N51-FLT3 and N73-FLT3, and the association of Shp2 and STAT5 in total cell 
lysates.  We further used immunoblot analysis to determine the levels of phosphorylated- 
and total-Shp2 protein expression, and the activation of STAT5.  
To study the potential role of Shp2 in the nucleus of FLT3-ITD-expressing cells, 
immunofluorescence and chromatin immunoprecipitation (ChIP) assays were utilized to 
demonstrate  nuclear co-localization of Shp2 with phospho-STAT5 and the presence of 
Shp2 at the STAT5-responsive promoter,  BCL2L1, which regulates expression of the 
pro-survival protein, Bcl-XL.   
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 To examine the contribution of Shp2 in FLT3-ITD-induced myeloproliferative 
disorder (MPD) in vivo, Shp2flox/flox;Mx1Cre genetic knock out animals were utilized by 
examining the effect of in vivo deletion of Shp2 on the latency to malignancy in animals 
transplanted with N51-FLT3-transduced Shp2flox/flox;Mx1Cre cells.  Finally, using a 
syngeneic N51-FLT3 transplant model, we examined the effect of in vivo treatment with 
the Shp2 pharmacologic inhibitor, II-B08.   
 
Significance 
 While acute myeloid leukemia is a relatively rare disease, it accounts for 
approximately 40% of all leukemias in the western world.  Therapies to treat patients 
with FLT3-ITD-positive acute myeloid leukemia typically involve harsh regimens of 
chemotherapy and radiation and even then prognosis remains poor, rendering supportive 
care often one of the only remaining options.   
 Our efforts to identify Shp2 as an important, targetable signaling molecule for 
molecularly targeted therapeutic treatment of these patients are significant because they 
allow us to better understand the molecular mechanisms contributing to FLT3-ITD+ 
cellular transformation.  Ultimately, this has enabled us to study genetic deletion of Shp2 
and the use of a pharmacologic inhibitor targeted to Shp2 in order to demonstrate that 
targeting Shp2 may have therapeutic benefits to FLT3-ITD+ AML patients.  Because 
Shp2 has been implicated in many different types of malignancies as well as congenital 
disorders, a better understanding of its molecular mechanisms in FLT3-ITD+ AML opens 
the possibilities for potential therapeutic options for these other Shp2-related disorders.   
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CHAPTER TWO 
MATERIALS AND METHODS 
A.  Materials 
1.  Plasmids 
a.  pMSCV 
pMSCV:  WT-, N51-, and N73-FLT3 constructs were expressed using the Murine Stem 
Cell Virus (pMSCV) plasmid.  cDNA from human WT-FLT3, or patient-derived FLT3-
ITDs, N51-FLT3, or N73-FLT3 were expressed in the bicistronic pMSCV vector, co-
expressing green fluorescent protein (GFP) as a marker.  FLT3-ITDs “N51-FLT3” and 
“N73-FLT3” have insertions/duplications of the following amino acids:  “REYEYDL” 
and “GLYVDFREYEY” respectively.  
 
2.  Primers 
Standard PCR reactions were performed using oligonucleotides synthesized by 
Invitrogen. 
 
Table 2.1:  Genotyping primers 
Gene Forward (5′-3′) Reverse (5′-3′) 
Shp2flox 5’-ACGTCATGATCCGCTGTCAG-5’ 5’-ATGGGAGGGACAGTGCAGTG-3’ 
Cre 5’-CTGGCAATTTCGGCTATACGTAACAGGGTG-3’ 5’-GCCTGCATTACCGGTCGATGCAACGAGTG-3’ 
Shp2null 5’-AAGAGGAAATAGGAAGCATTGAGGA-3’ 5’-TAGGGAATGTGACAAGAAAGCAGTC-3’ 
 
Table 2.2:  Quantitative PCR primers 
Gene Forward (5′-3′) Reverse (5′-3′) 
Bcl-XL 5’-CCCAGGGAGTGACTTTCCGAGG-3’ 5’-TCGAAAGCACCAGTGGACTCTGA-3’ 
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3.  Patient Samples 
 
Patient, peripheral blood, or bone marrow aspirate samples were obtained with prior 
patient consent.  Using ficol gradient, low density mononuclear cells were isolated and 
given to us by Dr. Scott Boswell’s lab under the Institutional Review Board (IRB)  
#9812-11 (Principle investigator, Dr. Larry Cripe). 
 
4.  shRNA plasmids 
shRNA vectors are pRS plasmids with the shRNA driven by the U6 promoter for 
mammalian cell expression.  Four different shRNA sequences targeted to Shp2 were 
given as well as an empty vector control and a scrambled, non-targeting control and are 
seen in the table below:   
Table 2.3:  shRNA Plasmids 
ID Name shRNA sequence 
TI525710 Shp2 shRNA-10 TAGTGAAACGGTCATTCAGCCACTGAATA 
TI525711 Shp2 shRNA-11 GTTTGAGACGCTCCAGCAACAGGAATGCA 
TI525712 Shp2 shRNA-12 ATGGATGTCCAGCACTACATAGAGACGCT 
TI525713 Shp2 shRNA-13 CTGGCGGATGGTGTTCCAGGAGAACTCTC 
TR20003 Shp2 shRNA-vector None 
TR30003 Shp2-shGFP scrambled Not given 
 
 
5.  Mice 
a.  C57Bl/6 
C57Bl/6 mice were received from Harlan and used to isolate wild type bone marrow low 
density mononuclear cells. 
b.  Shp2flox/flox 
Shp2flox/flox animals were given to us by Dr. Gen-Sheng Feng and crossed with Mx1-Cre 
animals which we received from Dr. Reuben Kapur. 
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c.  Mx1-Cre+ 
Mx1-Cre animlas were a generous gift from Dr. Reuben Kapur. 
d.  F1 (C57/BoyJ F1) 
F1 transplant recipient mice were purchased from the In Vivo Therapeutics Core at 
Indiana University School of Medicine. 
 
6.  Antibodies 
Table 2.4:  Primary Antibodies 
Primary Antibodies Company Clone 
T-Akt Cell Signaling N/A 
P-Akt (S473) Cell Signaling 587F11 
P-Erk Cell Signaling N/A 
T-Erk Cell Signaling N/A 
P-STAT5 (Y694) Cell Signaling N/A 
T-STAT5 Cell Signaling 3H7 
T-STAT5 (Chip assay) Santa Cruz N-20 
FLT3 Santa Cruz C-20 
T-Shp2 Santa Cruz C-18 
P-Shp2(Y580) Cell Signaling N/A 
Ras Millipore RAS 10 
GAPDH Biodesign International 6C5 
PARP1 Santa Cruz A-20 
P-STAT5-APC (PY694) BD N/A 
APC Mouse IgG1, k isotype Biolegend N/A 
Annexin-V-APC BD Pharmingen N/A 
CD45.1-PE eBioscience A20 
 
Rat IgG2a Isotype (PE) eBioscience eBR2a 
 
CD45.2-APC eBioscience 104 
Rat IgG2a Isotype (ACP) eBioscience eBR21 
 
 
Table 2.5:  HRP Secondary Antibodies 
Secondary Antibody Vendor 
Goat Anti-Rabbit IgG HRP Santa Cruz 
Goat Anti-Mouse IgG HRP Santa Cruz 
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7.  Kits 
Table 2.6:  Kits 
Kit Vendor Catalog Number 
NE-PER Nuclear/Cytoplasmic Extraction 
Kit Thermo Scientific PI-78833 
ChIP assay kit Millipore  17-295 
Hematopoietic progenitor and stem cell 
enrichment kit 
EasySep, Stem 
Cell Technologies 19756 
Plasmid Maxi-Prep Kit Invitrogen K210007 
SuperSignal West Dura Extended Duration 
Substrate Thermo Scientific 34076 
Mini-prep kit Qiagen 27106 
TOPO TA Cloning Kit for Sequencing Invitrogen K459501 
Profection Mammalian Transfection 
System Promega E1200 
Ras Activation Assay Kit Millipore 17-218 
Nucleofector Kit V Amaza/Lonza VCA-1003 
Annexin V Apoptosis Kit BD Pharmigen 556547 
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B.  Methods 
 
1.  Cell Culture 
a.  32D Cells 
32D cells, American Type Culture Collection (ATCC) were cultured in IMDM 
(Invitrogen), 10% FBS (HyClone), 1% Penicillin/streptomycin (Invitrogen), and 10ng/ml 
IL-3 (PeproTech).  Cells were grown at 37˚C and 5% CO2. Cells were split every 2-4 
days. 
b. Baf3 Cells 
Baf3 cells (ATCC), were maintained in IMDM (Invitrogen) supplemented with 10% fetal 
bovine serum (FBS) (HyClone), 1% penicillin/streptomycin (Gibco), and 5ng/ml IL-3 
(PreproTech).  Cells were grown at 37˚C and 5% CO2.  Cells were split every 2-4 days.  
Baf3 cells expressing WT-, N51-, or N73-FLT3 express neomycin resistance and are 
therefore also cultured with 40µl/ml genetecin (Invitrogen).  
c.  HL-60 
HL-60 cells (ACTT) are cultured in RPMI (Invitrogen), supplemented with 10% FBS 
(HyClone) and 1% Penicillin/streptomycin at 37˚C and 5% CO2.  Cells were split every 
2-4 days. 
d.  MV411 
MV411 cells are cultured in McCoy’s 5A media (Invitrogen), 10% FBS (HyClone), and 
1% Penicillin/streptomycin (Invitrogen).  Cells were grown at 37˚C and 5% CO2.  Cells 
were split every 2-4 days. 
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e.  Primary Low Density Mononuclear Cells (LDMNCs) 
Primary murine LDMNCs are cultured in MEM-alpha (Invitrogen), 20% FBS (HyClone), 
2% Penicillin/streptomycin (Invitrogen), Granulocye-Colony Stimulating Factor (G-
CSF), Stem Cell Factor (SCF) and Thrombopoietin (TPO) at 100ng/ml concentration 
each.  LDMNCs are maintained at 37˚C and 5% CO2.  LDMNCs are grown for up to a 
maximum of 9-10 days, changing their media every 2-4 days. 
f.  Macrophage Progenitors 
Primary LDMNCs are cultured in IMDM (Invitrogen), 20% FBS (HyClone), 1% 
Penicillin/streptomycin, and 50ng/ml macrophage-colony stimulating factor (M-CSF) for 
7-10 days at 37˚C and 5% CO2 to generate adherent macrophage progenitors.  
Macrophage progenitors require additional media after 2-3 days to supplement their 
growth before they become adherent.  A full media change is required after they become 
adherent at day 5-6, and every 2-3 days thereafter.    
g.  Phoenix-GP Packaging Cells 
Phoenix-GP cells are cultured in DMEM (Invitrogen), supplemented with 10% FBS 
(HyClone), 1% L-glutamine, and 2% penicillin/streptomycin on gelatin-coated, tissue 
culture treated 10-cm plates at 37˚C and 5% CO2.  Cells are split every 2-3 days.   
 
2.  Thymidine Incorporation Assays   
Cell were starved for 4-6 hours (Baf3 cells overnight) in serum-free IMDM and then 
plated into thymidine incorporation assays (1-5 x 104 cells/200 ul) either at baseline (no 
growth factor) or in the presence of 50 or 100ng/ml FLT3 ligand (FL), with or without 
indicated inhibitors and incubated overnight at 37˚C.  The following morning, cells were 
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pulsed with 1µCi tritiated thymidine and incubated for 5-6 hours at 37˚C.  Thymidine 
incorporation was determined using automated 96-well cell harvester (Brandel, 
Gaithersburg, MD). 
 
3.  Retroviral Supernatant Production 
Pheonix-GP packaging cell lines are grown in DMEM + 10% FBS + 1% L-glutamine 
(Gibco, 25030) and 2% penicillin/streptomycin.  Retroviral supernatants were produced 
by transfecting the phoenix cells with retroviral vector plasmids using calcium phosphate 
transfection (ProFection® Mammalian Transfection System, Promega, Madison, WI).  
Supernatants, collected at 48, 60 and 72 hours post-transfection were filtered through 
0.45 micron filters and concentrated 1:4 by ultra-centrifugation.   
 
4.  Retroviral Transduction   
a.  Primary murine cells 
Low density mononuclear (LDMNCs) cells were transduced with 2ml pMSCV, pMSCV-
WT-FLT3 or pMSCV-N51-FLT3 retroviral supernatant, supplemented with 100ng/ml 
TPO, SCF, and G-CSF in retronectin-coated, 6cm non-tissue culture plates for 24 hours 
at 37˚C.  After 24 hours, cells were collected, transduced again, (fresh retroviral 
supernatant and growth factors), and incubated overnight at 37˚C.  The following 
morning, cells were collected and plated back into prestimulation media for 24 hours.  
b.  Baf3 cells  
Baf3 cells were transduced similarly to LDMNCs (above) with the following 
modifications.  Cells were supplemented with 10ng/ml IL-3 and plated into 6-well plates.  
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They were then spun for 1 hour at 1,200 rpm to help ensure the virus and cells were in 
very close proximity to each other prior to incubation at 37˚C.   
 
5.  Cell Sorting    
Retrvirally transduced cells are collected and sorted using fluorescence-activated cell 
sorting (FACS) analysis, collecting enhanced green fluorescent protein positive (EGFP+) 
cells. 
 
6.  Immunoprecipitation and Immunoblots 
0.5-1mg total cell lysates were immunoprecipitated with anti-FLT3, anti-Shp2, or anti-
STAT5 and protein-A sepharose beads (Cl-4B, GE Healthcare) in HNTG buffer (20mM 
Hepes (pH 7.5), 150mM NaCl, 1% Triton X-100, 10% glycerol, plus fresh inhibitors 
(1mM Na3VO4, 0.1mM ZnCl2, 1mM PMSF, 10µl/ml sigma protease inhibitor)) overnight 
while rotating at 4˚C.  The following day, beads were centrifuged and washed several 
times with cold HNTG buffer, and immunoprecipitated proteins resuspended in sample 
buffer.  IP products were run on SDS-PAGE gels, and blots were probed with indicated 
primary antibody, incubated with secondary antibody, and imaged.   
 
7.  Apoptosis Assay 
Sorted, EGFP+, bone marrow LDMNCs expressing either WT-FLT3 or N51-FLT3 were 
prestimulated for 24-48 hours.  Cells were then collected and counted.  225,000 cells 
were plated into 12-well non tissue culture plates in baseline (2%FBS-IMDM) media or 
in the presence of DMSO (4.5µl) 5µM, 15µM, or 30µM II-B08 in a total volume of 
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500µl and incubated overnight at 37˚C.  The following day cells were carefully collected 
into individual 5ml polystyrene tubes (FACS tubes), washed with PBS and resuspended 
in 100µl 1X buffer (BD Pharmingen FITC-Apoptosis Detection Kit I #556547 with APC-
Annexin-V #51-65874X (556420)) supplemented with 5µl propidium Iodide (BD#51-
66211E(556463)) and 5µl Annexin-V-APC.  Cells were incubated in the dark at room 
temperature for 30 minutes to stain.  Finally, 200-400µl of 1X buffer was added and 
FACS analysis performed using the FACSCalibur APC flow cytometry machine.   
 
8.  Phospho-STAT5 staining  
Sorted, EGFP+ WT-FLT3 or N51-FLT3-expressing polyI/polyC-treated 
Shp2flox/flox;Mx1-Cre- or Shp2flox/flox;Mx1-Cre+ cells were fixed in 1.5% formaldehyde 
(stock 37%) at room temperature for 10 minutes at 37˚C.  Cells were then collected, 
centrifuged and resuspend in 100% ice cold methanol at 4˚C at a concentration of 1 x 106 
cells/ml methanol, vortexed, and incubated at 4˚C for 10 minutes.  3ml of FACS buffer 
was added to each tube and cells were pelleted and washed a second time with 3ml FACS 
buffer.  Cells were then resuspend in 100µl of FACS buffer, split into two tubes and 
either 20µl conjugated antibody (BD, Alexa Fluor 647 mouse Anti-STAT5 (PY694), or 
1µl isotype (Biolegend APC Mouse IgG1, k isotype) added.  Cells were kept in the dark 
at room temperature for 30 minutes to stain and then washed with 3ml FACS buffer.  
Finally, cells were resuspend in 500µl FACS buffer and analyzed using the Accuri flow 
cytometer.   
30 
 
9.  Transplants 
Bone marrow LDMNCs were isolated from Shp2flox/flox;Mx1cre+animals (C57Bl/6 
background) and subjected to negative selection for isolation of lineage negative (Lin-) 
cells for enrichment of hematopoietic progenitors and stem cells.  Lin- cells were 
retrovirally transduced with pMSCV-N51-FLT3 and sorted to homogeneity as described 
above.  1 x 106 transduced cells were transplanted by intravenous injection with 150,000 
supporting splenocytes into lethally irradiated (1100cGy split dose) F1 recipient animals.  
Transplanted animals were permitted to recover for 4 weeks, and then animals were 
separated into two groups with equal CD45.2 chimerism, EGFP expression, and WBC 
counts for treatment with either PBS (positive control animals) or 300µg polyI/polyC for 
deletion of Ptpn11 floxed sequences (experimental animals).  Animals were followed for 
12 months with assessment of chimerism every 4-6 weeks and evaluation of spleen size 
and histopathological diagnosis at the time of death.     
 
10.  Statistical Analysis in vivo 
The Leukemia Specific Survival is analyzed using the Kaplan Meier estimation method 
where leukemia related death are the events.  Both Mice that are alive at the last day of 
follow-up are incorporated into the analysis with time to event censored as the last day 
known alive.  Mice whose deaths are not related to leukemia are also incorporated into 
the analysis with time to event censored as the death time.  P-values are generated using 
the log-rank tests.  Statistical significance is set at 0.05 level.  
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11.  Immunofluorescence  
Briefly, 1.2 x 106 MV4-11 or HL-60 cells were loaded into 35-mm glass-bottom 
microwell dishes (MatTek Cultureware, Ashland, MA; Gamma irradiated, TK0275), 
centrifuged at 1400rpm for 5min at room temperature, fixed with cold methanol/acetone 
(1/1) for 10 minutes at -20˚C, and air dried at room temperature for 15min.  Cells were 
blocked with 2%BSA, 10% goat serum in PBS, incubated with anti-Shp2 ( BD 
Biosciences, #610621) or anti-phosphorylated STAT5 (Cell Signaling Technology, 
#9314), secondarily stained with Alexa-647 goat anti-mouse and Alexa-488 goat anti-
rabbit, respectively, and counterstained with DAPI 5µg/mL.  Cells were imaged on 
Olympus FV1000-MPE confocal/multiphoton microscope (Olympus America Inc, Center 
Vally, PA0 using UPLAPO 60X W/NA:1.20 objective Lens. Samples were scanned at 
405nm, 488nm, 635nm excitation wavelength, and images were collected at 461nm, 
520nm, and 668nm emission wavelength, respectively.  The system is mounted on an 
Olympus IX81 inverted microscope stand. Images shown are representative of at least 2 
independent experiments. MetaMorph (Universal Imaging, Downington, PA) was used 
for image handling. 
 
12.  Chromatin Immunoprecipitation Assay 
Chromatin immunoprecipitation (ChIP) assays were performed using a ChIP assay kit 
(Upstate Biotechnolgy).  Briefly, MV411 and HL60 cells were treated with 1% 
formaldehyde for cross-linking followed by preparation of cellular extracts using lysis 
buffer (1% SDS, 10 mM EDTA, and 50 mM Tris-HCL, pH 8.1).  Extracts were sonicated 
to shear chromatin DNA to produce 500-1000 bp DNA fragments followed by incubation 
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with anti-STAT5, anti-Shp2, or normal rabbit IgG (Millipore) and salmon sperm 
DNA/Protein A agarose in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 
mM EDTA, 16.7 mM Tris-HCL, pH 8.1, and 167 mM NaCl) overnight at 4˚C.  
Immunoprecipitates were collected by gentle centrifugation, washed, and eluted with low 
and high stringency buffers.  Histone-DNA crosslinks were reversed by heating for 4 
hours at 65˚C, proteins were digested by treatment with proteinase K, and DNA was 
recovered by phenol/chloroform extraction.  Quantitative PCR using SYBR green was 
conducted using forward primer 5’-CCC AGG GAG TGA CTT TCC GAG GAA-3’ and 
reverse primer 5’-TCG AAA GCA CCA GTG GAC TCT GA-3’, which generate a 90 bp 
band spanning the human BCL2L1 promoter including two interferon γ activation sites 
(gAS, consensus sequence TTCN2-N4GAA) by which STAT5 has been shown to 
transactivate gene expression.  Immunoprecipitated fragments were expressed as a 
percentage of the total chromatin used in the sample.  Amplified fragments were 
additionally electrophoresed on agarose gels to validate fragment size and fragments 
were subcloned for sequence verification of the predicted BCL2L1 promoter fragment. 
 
13.  Ras Activation Assay 
Ras Activation Assays were performed using the manufactures directions (Millipore, 
catalog number 17-218).  Briefly, cells were treated in the absence or presence of the 
indicated amount of II-B08 for 5 or 60 minutes.  Cells were then collected on ice, washed 
with ice cold PBS, and lysed in MLB buffer.  Lysates were centrifuge to remove any 
cellular debris (supernatant retained), quantified immediately and immunoprecipitation 
set up for a 45-minute incubation with Ras Assay Reagent (Raf-1 RBD agarose).  Next, 
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beads were centrifuged and washed 3 times with MLB.  Beads were finally resuspended 
in sample buffer to liberate the pull-down products, boiled, and run by immunoblot 
analysis, probing with anti-Ras antibody.   
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CHAPTER THREE 
REDUCED SHP2 EXPRESSION INHIBITS FLT3-ITD-INDUCED 
HYPERPROLIFERATION IN BAF3 CELLS 
Introduction 
It is well established that FLT3-ITDs confer a poor prognosis in all AML patients, 
including the elderly (Whitman, Archer et al. 2001).  Elderly patients are at an increased 
susceptibility to mortality from AML for several reasons.  First of all, AML is more 
prevalent in aging individuals and the elderly are more likely to have co-morbidities, such 
as diabetes and heart disease, rendering standard chemotherapy and radiation regimens 
too harsh for these patients to sustain.  Therefore, we are interested in better 
understanding the molecular mechanisms contributing to FLT3-ITD-induced 
leukemogenesis in order to identify novel and less toxic therapeutic approaches which 
may be beneficial in treating FLT3-ITD-positive AML patients.   
Baf3 cells are an immortalized, murine, pro-B, IL3-dependent cell line.  They do 
not endogenously express FLT3 receptors, therefore they are an attractive model to 
examine the effects of FLT3-ITDs.  Baf3 cells are particularly useful because they can be 
easily cultured to generate large amounts of cells for biochemical assays.  They are also 
easily transfected or transduced to express additional proteins of interest.  Baf3 cells 
expressing WT-FLT3, N51-FLT3, and N73-FLT3 were a generous gift from Dr. Seiji 
Fukuda (Fukuda, Broxmeyer et al. 2005) and were used for the following studies.  The 
transduced Baf3 cells express a neomycin resistance gene in addition to the FLT3 cDNA 
and are therefore cultured in the presence of 40µl/ml geneticine to maintain stable cell 
lines.   
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Given that FLT3-ITD often duplicate Y599, the site of Shp2 recruitment to WT-
FLT3, we hypothesized that in the presence of N51- and N73-FLT3 there would be an 
increased association of Shp2 to the mutant FLT3 receptor and this interaction would 
contribute to the activation of STAT5 and its transcriptional targets.  I used these cells in 
biochemical studies to examine the potential interaction between the protein tyrosine 
phosphatase, Shp2, and FLT3 or STAT5.  I also conducted functional assays examining if 
knockdown of Shp2 expression resulted in reduced FLT3-ITD-induced 
hyperproliferation.  Finally, using a human, FLT3-ITD-positive cell line, MV411, I 
examined the nuclear association of Shp2 and its potential co-localization with STAT5 at 
STAT5-responsive promoter element BCL2L1.  
 
Results 
 
Baf3 cells stably expressing N51-FLT3 or N73-FLT3 are hyperproliferative 
Previous studies had indicated that the FLT3-ITD mutants, N51 and N73, confer 
ligand-independent hyperproliferation and STAT5 hyperphosphorylation; however, we 
wished to verify these findings in the N51-FLT3- and N71-FLT3-transduced cell lines.  
Therefore, we examined the proliferation of Baf3 cell lines stably expressing WT-FLT3, 
N51-FLT3, or N73-FLT3 (Figure 3.1A).  Each cell line was starved overnight in serum-
free IMDM and then plated into thymidine incorporation assays (1-5 x 104 cells/200µl) 
either at baseline (no growth factor) or in the presence of 50 or 100ng/ml FLT3 ligand 
(FL) and incubated overnight at 37˚C.  The following morning, cells were pulsed with 1 
µCi tritiated thymidine and incubated for 5-6 hours at 37˚C.  Thymidine incorporation 
was determined using automated 96-well cell harvester (Brandel, Gaithersburg, MD).  
WT-FLT3-expressing Baf3 cells were quiescent at baseline and demonstrated increased 
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proliferation in a FL-dependent manner (Figure 3.1A).  However, both N51-FLT3- and 
N73-FLT3-expressing Baf3 cells were constitutively hyperproliferative at baseline and 
could not be further induced to proliferate by FL stimulation (Figure 3.1A).  We next 
prepared total cell lysates from each cell line to examine FLT3 expression levels.  Total 
cellular extracts were electorphoresed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), transferred to nitrocellulose and probed with α-FLT3 
(Figure 3.1B).  Expression levels of WT-FLT3 and N73-FLT3 were very similar 
suggesting the hyperproliferation of N73-FLT3 is due to the contribution of the gain-of-
function FLT3-ITD.  The protein expression of N51-FLT3 was, however, higher than that 
of WT-FLT3 or N73-FLT3, which may partially explain the increased level of N51-
induced hyperproliferation compared to that of N73-FLT3, particularly in the absence of 
FL (Figure 3.1A).  
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Figure 3.1:  Baf3 cells expressing N51- or N73-FLT3 are hyperproliferative and 
express constitutively activated STAT5 
 
(A) Baf3 cells expressing WT-, N51-, or N73-FLT3 were subjected to thymidine 
incorporation assays in the absence (baseline) or presence of 50 or 100ng/ml FL; N=4; 
statistics were determined by unpaired, two-tailed T-test; *p<0.001 for N51 vs WT  
**p<0.001 for N73 vs. WT, at baseline and in response to FL at 50ng/ml and 100ng/ml.  
(B)  Immunoblot analysis of total cell lysates from nascent Baf3 cells, or those expressing 
WT-, N51-, or N73-FLT3, probed with α-FLT3 or α-GAPDH.  (C) Immunoblot 
demonstrating phospho (P)-STAT5 in WT-, N51-, and N73-FLT3-expressing Baf3 cells.   
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Baf3/N51-FLT3 and Baf3/N73-FLT3 cells exhibit constitutive activation of STAT5 
It has been well demonstrated that in the presence of FLT3-ITDs, STAT5 is 
constitutively activated (Mizuki, Schwable et al. 2003; Chung, Morrone et al. 2005; Kato, 
Iwama et al. 2005; Rocnik, Okabe et al. 2006; Choudhary, Brandts et al. 2007).  To 
further investigate the molecular mechanism underlying the hyperproliferation of N51- 
and N73-FLT3, we used the WT-FLT3-, N51-FLT3-, and N73-FLT3-transduced Baf3 
cell lines for biochemical analysis.  Cells were starved overnight in IMDM.  The 
following morning, cells were collected (baseline) and stimulated for 5, 10, or 30 minutes 
with FL (100ng/ml).  Total cell lysates were electorphoresed by SDS-PAGE, transferred 
to nitrocellulose membrane, and probed with α-P-STAT5 or α-T-STAT5.  Figure 3.1C 
demonstrates that STAT5 is modestly activated by WT-FLT3 in response to FL 
stimulation (lanes 1-4).  However, STAT5 is constitutively phosphorylated in cells 
expressing N51-FLT3 (lanes 5-8) and N73-FLT3 (lanes 9-12) independent of FL 
stimulation.  Consistent with increased baseline proliferation and increased FLT3 
expression, the N51-FLT3-transduced cells demonstrate the most robust level of STAT5 
activation.  Collectively, our results are consistent with previous studies that FLT3-ITDs 
induce FL-independent constitutive activation of STAT5.   
 
Co-immunoprecipitation reveals that Shp2 is constitutively associated to FLT3 in Baf3 
cells expressing N51-FLT3 or N73-FLT3 and in the human FLT3-ITD+ cell line, 
MV411 
 Since Y599 of WT-FLT3 was shown to recruit Shp2 in biochemical studies 
(Heiss, Masson et al. 2006), and since Y599 is commonly duplicated in FLT3-ITD 
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mutations, we next examined the ability of N51- and N73-FLT3 to recruit Shp2 
compared to that of WT-FLT3.  Using the Baf3-transduced cell lines, previously 
described, cells were starved overnight in IMDM and collected (baseline) or stimulated 
with 100ng/ml FL for the indicated amount of time.  Total cell lysates were prepared and 
used in co-immunoprecipitation assays.  One mg of protein was immunoprecipitated with 
α-FLT3 and immunoblotted with α-Shp2.  These results demonstrate that Shp2 is 
recruited to WT-FLT3 in a FL-dependent manner (Figure 3.2A and 3.2B, lanes 1-2) and 
this association diminishes over time (Figure 3.2B, lanes 1-4).  On the contrary, Shp2 is 
strongly and constitutively associated to N51-FLT3 (Figure 3.2A, lanes 3-4) and N73-
FLT3 (Figure 3.2B, lanes 5-8) regardless of FL-stimulation.  These findings support our 
hypothesis that there is an increased recruitment of Shp2 to FLT3-ITDs. 
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Figure 3.2:  Shp2 is constitutively associated to FLT3-ITDs in transduced Baf3 cells 
 
Total cell lysates from Baf3 cells expressing WT-FLT3 (A, B), N51-FLT3 (A), or N73-
FLT3 (B) were immunoprecipitated (IP) with α-FLT3 and immunobloted (IB) with α-
Shp2.   
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In addition to the Baf3 cell lines, we also utilized the human AML cell lines HL60 
(WT-FLT3 expressing; ITD negative) and MV411 (FLT3-ITD positive).  The MV411 
cell line serves as a good model as it is derived from a FLT3-ITD+ patient sample, the 
FLT3-ITD expression is regulated by endogenous genomic promoter elements, and the 
cell line manifests constitutively active STAT5 (Figure 3.3A).  Total cell lysates were 
prepared from exponentially growing MV411 and HL60 cells and subjected to 
immunoprecipitation assays.  Lysates were immunoprecipitated with α-FLT3 and 
immunobloted with α-Shp2.  A minimal amount of Shp2 was associated with WT-FLT3 
in the HL60 cells (Figure 3.3B).  However, there was a strong association of Shp2 to 
FLT3-ITD in the lysates from MV411 cells (Figure 3.3B).  Furthermore, we found that 
Shp2 is constitutively associated with FLT3 in a FLT3-ITD+ primary AML sample 
(Figure 3.3B, patient # 2797) and to a lesser extent in two FLT3-ITD- primary AML 
samples (Figure 3.3B, patient #s 2944 and 2945).  Collectively, these data provide 
biochemical evidence using cell lines and primary AML samples that Shp2 is 
constitutively associated with FLT3-ITD and suggest that Shp2 may play a positive role 
in mediating FLT3-ITD-induced hyperproliferation. 
42 
 
 
Figure 3.3:  Shp2 is constitutively associated to FLT3-ITD in FLT3-ITD+ MV411 
cells and in primary AML samples 
 
(A) Intracellular staining of phospho-STAT5 in MV411 and HL60 cells assessed by flow 
cytometry.  (B) Total cell lysates from MV411 cells (FLT3-ITD+), HL60 cells (FLT3-
ITD-), or primary AML cells were immunoprecipitated (IP) with α-FLT3 and 
immunobloted (IB) with α-Shp2.   
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Shp2 and STAT5 co-localize in the presence of N51-FLT3 
To further investigate the relationship between Shp2 and FLT3-ITDs we were 
interested in the potential interaction between Shp2 and STAT5.  While Shp2 has been 
shown to negatively regulate STAT5 by some studies (Yu, Jin et al. 2000; Chen, Wen et 
al. 2003); it has paradoxically been shown to positively regulate STAT5 by others (Ke, 
Lesperance et al. 2006; Choudhary, Brandts et al. 2007).  In the regulation of the β-casein 
gene in mammary epithelial cells, Shp2 was shown to interact directly with STAT5.  
Since we observed a constitutive association of Shp2 to FLT3-ITDs, we hypothesized 
that Shp2 acts to positively regulate STAT5 in the presence of FLT3-ITDs.  To initially 
address this hypothesis, we examined the potential interaction between STAT5 and Shp2 
in FLT3-ITD-expressing cells.  Using total cell lysates from WT-FLT3 and N51-FLT3-
expressing Baf3 cells, we immunoprecipitated with α-Shp2 (Figure 3.4A) or α-STAT5 
(Figure 3.4B) and immunobloted with α-STAT5 or α-Shp2, respectively.  This 
experiment demonstrated a modest association of Shp2 to STAT5 in the WT-FLT3-
expressing Baf3 cells.  On the contrary, there was a robust association of Shp2 to STAT5 
in the Baf3/N51-FLT3 cell line.  The membranes were then stripped and re-blotted with 
either α-Shp2 or α-STAT5 as a control.  These data suggest that the increased recruitment 
of Shp2 to FLT3-ITDs may subsequently lead to an increased association and/or 
activation of STAT5 and suggest that Shp2 cooperates with FLT3-ITDs or subsequently 
with STAT5 to promote hyperproliferation of FLT3-ITD-expressing cells.  As a result, 
we next investigated the effect of reduced Shp2 protein expression on FLT3-ITD-induced 
hyperproliferation.   
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Figure 3.4:  Shp2 and STAT5 interaction is increased in N51-FLT3-expressing cells 
 
Total cell lysates from Baf3/WT- and Baf3/N51-FLT3 were immunoprecipitated with 
either α-Shp2 (A) or α-STAT5 (B) and immunobloted with α-STAT5 or α-Shp2, 
respectively, to examine the interaction between Shp2 and STAT5 in the presence of 
N51-FLT3 compared to WT-FLT3.  Membranes were then stripped and re-probed for 
either α-Shp2 (A) or α-STAT5 (B).   
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shRNA targeted to Shp2 significantly reduces hyperproliferation of Baf3 cells 
expressing either N51-FLT3 or N73-FLT3 
We hypothesized that reduced Shp2 protein expression would subsequently result 
in reduced hyperproliferation induced by N51-FLT3 and N73-FLT3.  We transfected the 
previously described Baf3 cells with plasmids encoding short hairpin RNA (shRNA) 
targeted to Shp2 or a scrambled control (Origene #TR501795) by nucleofection (Amaxa 
Nucleofection Kit V) and selected the cells in 1µg/ml puromycin to create stable cell 
lines (Figure 3.5).  After selection in puromycin, immunoblot demonstrated reduced Shp2 
protein expression by at least 50% in cells transfected with shRNA targeted to Shp2 (KD) 
compared to scrambled control (SC) in Baf3/WT-FLT3 (Figure 3.6A and 3.6B), 
Baf3/N51-FLT3 (Figure 3.6A) and Baf3/N73-FLT3 (Figure 3.6B) cells.   
To investigate the functional relevance of reduced Shp2 on activating FLT3-
induced hyperproliferation, cells were starved for 6 hours in IMDM, plated into 96-well 
plates in either starvation media (baseline) or stimulated with 50 or 100ng/ml FL and 
subjected to thymidine incorporation assays (previously described).  Baf3/N51-FLT3 
(Figure 3.6C) and Baf3/N73-FLT3 (Figure 3.6D) cells transfected with shRNA-KD 
demonstrated significantly reduced proliferation at baseline and in response to FL, in 
contrast to that observed with Baf3/N51-FLT3 or Baf3/N73-FLT3 cells transfected with 
scrambled shRNA, suggesting a functional role of Shp2 in FLT3-ITD-induced 
hyperproliferation.  Furthermore, there is a correlation between Shp2 protein expression 
and proliferation.  When Shp2 protein levels are reduced by only 50% (Figure 3.6A), 
proliferation is similar between Baf3/WT-FLT3 cells expressing shRNA-SC and those 
expressing shRNA-KD (Figure 3.6C); however when Shp2 protein is more substantially  
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Figure 3.5:  shRNA transfection schematic to generate stable cells lines with reduced 
Shp2 expression 
   
U6 promoter driven shRNA constructs were transfected into Baf3/WT-, N51-, or N73-
FLT3 cells, and selected in 1µg/ml puromycin to generate stable cell lines.  Selected cells 
were subsequently used in thymidine incorporation assays as well as immunoblot 
analysis.   
 
 
 
 
Baf3-N51-Flt3Baf3-WT-Flt3
Select
1 µg/ml Puromycin
Western Blot AnalysisThymidine Incorporation
SC Shp2 KD Shp2 SC Shp2 KD Shp2 SC Shp2 KD Shp2
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reduced by approximately 70-80% (Figure 3.6B), Baf3/WT-FLT3 cells expressing 
shRNA-KD demonstrate a modest decrease in proliferation compared to Baf3/WT-FLT3 
cells expressing shRNA-SC at baseline and in response to FL (Figure 3.6D).  Since it has 
been demonstrated that Shp2 is required for WT-FLT3-induced proliferation (Heiss, 
Masson et al. 2006), it is not surprising that there is a modest reduction of WT-FLT3-ITD 
induced proliferation with a substantial reduction of Shp2.  Cells expressing FLT3-ITDs 
however, regardless of the level of Shp2 knockdown, demonstrate reduced proliferation, 
suggesting that FLT3-ITD-expressing cells are more sensitive to loss of Shp2 compared 
to WT FLT3-expressing cells.  This correlation of Shp2 expression with functional 
response further supports the hypothesis that Shp2 function contributes to FLT3-ITD-
induced cellular growth.  In order to further investigate the Shp2-STAT5 association 
exhibited in Figures 3.4A and 3.4B in Baf3/N51-FLT3 cells, we next considered possible 
molecular mechanisms.   
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Figure 3.6:  Reduced Shp2 protein expression significantly reduces 
hyperproliferation induced by N51-FLT3 and N73-FLT3 in Baf3 cells 
 
Baf3/WT-FLT3 and Baf3/N51-FLT3 (A) and Baf3/WT-FLT3 and Baf3/N73-FLT3 (B) 
cell lines transfected with scrambled shRNA (SC) or shRNA targeting Shp2 (KD) were 
used in immunoblot analyses and demonstrate at least 50% reduction in Shp2 protein 
levels in cells transfected with shRNA-KD compared to shRNA-SC (A, B) in each 
respective experiment.  Thymidine incorporation assays of Baf3/WT-FLT3 and 
Baf3/N51-FLT3 (C) and Baf3/WT-FLT3 and Baf3/N73-FLT3 (D) cell lines transfected 
with shRNA-SC or shRNA-KD.  Representative of two independent experiments (N=4, 
*p<0.02 for N51-KD v. N51-SC, *p<0.003 for N73-KD v. N73-SC, and ^p<0.02 for 
WT-KD v. WT-SC by unpaired, two-tailed T-test).   
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Shp2 and phospho-STAT5 co-localize in the nuclei of MV411 cells 
To investigate the interaction between Shp2 and STAT5 we used the human, 
FLT3-ITD-positive AML patient-derived cell line, MV411 and the human, FLT3-ITD-
negative myeloid leukemia patient-derived cell line, HL60.  The utilization of MV411 
cells is useful and applicable because not only were the cells derived from a human 
FLT3-ITD+ patient sample, but the FLT3-ITD is driven by endogenous promoter 
elements.  MV411 cells also have a strong hyperactivation of STAT5 compared to FLT3-
ITD- HL60 cells (Figure 3.3A) consistent with other reported FLT3-ITD-expressing 
cells.  Even though Shp2 is traditionally thought to be a cytosolic signaling molecule, it 
has been found in the nucleus of some AML samples (Xu, Yu et al. 2005), yet the role of 
nuclear-associated Shp2 in leukemogenesis has not been investigated.  We therefore 
examined cytoplasmic and nuclear extracts from both MV411 and HL60 cells.  Similar to 
previous studies, we found that MV411 cells had an increased level of phospho-STAT5 
and total-STAT5 in the nuclear fraction compared to the levels of STAT5 in HL60 cells 
(Figure 3.7A).  Interestingly, cytoplasmic and nuclear associated phospho-Shp2 was 
much higher in MV411 cells than in HL60 cells despite the fact that total-Shp2 protein 
levels were similar in both cytoplasmic and nuclear fractions of MV411 and HL60 cells 
(Figure 3.7A).  Considering that the nuclear fraction of MV411 cells is enriched in 
phospho-Shp2, we were next interested in examining the cellular localization and 
potential association of Shp2 and STAT5.   
To examine the physiologic, cellular localization of Shp2 and STAT5, I 
collaborated with Dr. Xingjun Li in our lab to perform the following in situ 
immunofluorescence studies to compare the nuclear distribution of Shp2 and the potential 
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co-localization of p-STAT5 in MV411 and HL60 cells.  Our results demonstrate that 
Shp2 and DAPI co-localize indicating that Shp2 is in the nucleus of both MV411 and 
HL60 cells (Figure 3.7B); however the distribution of Shp2 is much more clumped 
together in MV411 cells compared to a smooth distribution exhibited in HL60 cells.  
Consistent with many previous studies, p-STAT5 was much more intense in FLT3-ITD-
positive MV411 cells compared to weak p-STAT5 signal in HL60 cells (Figure 3.7B).  
Remarkably, upon merging the images, there is a robust co-localization of Shp2 and p-
STAT5 in the nucleus of MV411 cells (Figure 3.7B) which is absent in HL60 cells.  This 
Shp2-STAT5 nuclear co-localization in MV411 cells suggests that Shp2 may participate 
with (or in a complex with) STAT5 in the nucleus and may activate STAT5 
transcriptional targets promoting cellular transformation and leukemogenesis.   
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Figure 3.7:  Shp2 and phospho-STAT5 co-localize in the nuclei of MV411 cells 
 
Nuclear and cytoplasmic proteins were isolated from MV411 and HL-60 cells and 
assessed for phospho-STAT5 and phospho-Shp2 by immunoblot analysis (A).  
Immunostaining for Shp2 and phospho-STAT5 was performed in MV411 and HL60 cells 
and cells were imaged using confocal microscopy (B). 
A. 
B. 
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FLT3-ITD-expressing hematopoietic cells demonstrate increased association of the 
shp2-STAT5 complex at the BCL2L1 promoter 
Considering the nuclear co-localization of Shp2 and STAT5 in MV411 cells both 
biochemically and by immunofluorescence, we next hypothesized that Shp2 may be 
working in a complex with STAT5 to activate STAT5 transcriptional targets know to be 
implicated in leukemogenesis.  We decided to examine the BCL2L1 promoter which 
regulates the expression of Bcl-XL.  Pro-survival  protein Bcl-XL is an applicable target to 
investigate because its expression has been implicated in leukemogenesis (Beverly and 
Varmus 2009; Mizukawa, Wei et al. 2011), upregulated in hematopoietic progenitors 
expressing constitutive active STAT5 (Schuringa, Chung et al. 2004), and downregulated 
in hematopoietic progenitors expressing knockdown of Shp2 expression (Li, Modi et al. 
2011).  The human BCL2L1 promoter region has two functional interferon-γ activation 
sites (GAS, consensus sequence TTCN2-N4GAA) which are located upstream of the Bcl-
XL start codon (Figure 3.8A, -321 to -329 and -335 and -344 highlighted in red, atg 
underlined), and bind STAT5 to regulate the BCL2L1 promoter.  To examine the 
hypothesis that Shp2 is co-localized and participates with STAT5 at the endogenous 
promoter BCL2L1, we performed chromatin immunoprecipitation (ChIP) assays.  As 
expected and as a positive control we found increased amplification of the BCL2L1 
promoter region upon immunoprecipitation with α-STAT5 in the MV411 cells compared 
to the HL60 cells (Figure 3.8B).  Immunoprecipitation with α-Shp2 consistently yielded 
increased levels of the amplified BCL2L1 promoter region in MV411 cells compared to 
HL60 cells (Figure 3.8B) suggesting that Shp2 is functioning in a complex binding the 
GAS consensus sequence.  To verify the identity of the predicted amplified BCL2L1 
53 
 
promoter region, we subcloned amplified PCR products immunoprecipitated with either 
α-STAT5 or α-Shp2 into TOPO vectors and sequenced them (data not shown).  Together 
the immunofluorescence and ChIP data support the novel finding that Shp2 co-localizes 
with STAT5 in the nucleus of FLT3-ITD-expressing hematopoietic cells and contributes 
to the activation of pro-leukemic gene expression.   
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Figure 3.8:  FLT3-ITD-expressing hematopoietic cells demonstrate increased 
association of the Shp2-STAT5 complex at the Bcl-XL promoter 
 
Schematic diagram demonstrating the human BCL2L1 promoter with two functional 
interferon-γ activation sites (GAS sites, consensus sequence TTCN2-N4GAA) at -344 to 
-335 and -329 to – 321 upstream of the BclXL translation start codon highlighted in red 
with arrows indicating the primers used to amplify the region (A).  For ChIP assays, 
isolated lysates from HL60 or MV411 cells were immunoprecipitated with either anti-
STAT5 or anti-Shp2 followed by quantitative PCR using of purified DNA fragments 
using primers specific for the human BCL2L1 promoter (B).  The immunoprecipitated 
fragments were expressed as a percentage of the total chromatin used in the sample.  
Representative of 3 independent experiments, n=3, *p<0.005 for fragments pulled down 
by STAT5 from MV411 v. HL60 cells and **p<0.0005 for fragments pulled down by 
Shp2 from MV411 v. HL60 cells.  Unpaired, two-tailed, T-test used for statistics. 
A. 
B. 
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Conclusions 
 
 FLT3-ITD mutations confer a poor prognosis in AML patients, yet the molecular 
mechanisms of these mutations and their contributions to the disease phenotype remains 
poorly understood.  Baf3 cells expressing the FLT3-ITDs, N51-FLT3 and N73-FLT3, 
both exhibit ligand-independent hyperproliferation, while WT-FLT3 expressing cells are 
FL-dependent.  In addition to their hyperproliferative phenotype, the FLT3-ITD-
expressing cells also constitutively activate the transcription factor STAT5.  These 
studies support what has been previously demonstrated (Kiyoi, Ohno et al. 2002; Mizuki, 
Schwable et al. 2003; Chung, Morrone et al. 2005; Kato, Iwama et al. 2005; Rocnik, 
Okabe et al. 2006; Choudhary, Brandts et al. 2007) and provide evidence that this model 
recapitulates what has been observed by others and can be utilized to investigate the role 
of Shp2 in FLT3-ITD-induced STAT5 hyperactivation and hyperproliferation.      
In addition to these confirmatory studies, we have gone on to investigate the role 
of Shp2 in this system.  Since Y599 of WT-FLT3 has been shown to recruit Shp2, and 
FLT3-ITDs commonly contain a duplicated Y599, we hypothesized that Shp2 is 
constitutively associated with FLT3-ITDs and the additional and constitutive association 
of Shp2 participates in the hyperproliferation induced by these FLT3-ITDs.  
Immunoprecipitation assays demonstrated a constitutive association of Shp2 and FLT3 in 
N51-FLT3 and N73-ITD-expressisng Baf3 cells as well as in FLT3-ITD-positive MV411 
cells.  This is contrary to the ligand-dependent Shp2 association demonstrated in WT-
FLT3 expressing Baf3 cells.  Furthermore, we have demonstrated that reduction of Shp2 
protein expression by shRNA targeted to Shp2 significantly reduces the 
hyperproliferation induced by N51-FLT3 and N73-FLT3.   
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Shp2 has been shown to participate in the enhancement of cellular signaling 
(Neel, Gu et al. 2003; Chan and Feng 2007), however, a specific mechanism of how Shp2 
may act to promote leukemogenesis in the setting of FLT3-ITD and constitutive active 
STAT5 has not been elucidated.  While previous studies have demonstrated that Shp2 has 
been shown to be nuclear associated in AML samples (Xu, Yu et al. 2005), the role of 
Shp2 in the nuclear fraction of AML cells has not been examined.  Since the C-SH2 
domain has been demonstrated to be important in the activation of STAT5 in mammary 
epithelial cells (Chughtai, Schimchowitsch et al. 2002), we hypothesized that in the 
context of FLT3-ITD+ AML, Shp2 may function in a similar fashion, working with 
STAT5, to enhance pro-leukemic signals as a novel molecular mechanism for Shp2.  In 
support of our hypothesis, we demonstrated that Shp2 is co-localized with STAT5 in the 
nucleus of FLT3-ITD-bearing hematopoietic cells and present innovative ChIP data 
suggesting Shp2 is located in the protein complex located at the BCL2L1 promoter 
responsible for the transcription of pro-survival gene Bcl-XL.  To the best of our 
knowledge, this is the first time Shp2 has been found to function at a STAT5-responsive 
promoter sequence and suggests a new, novel role of Shp2 in the setting of 
leukemogenesis.   
Taken together, these results demonstrate a novel role of Shp2 functioning at the 
promoter element of STAT5 target gene Bcl-XL, and suggest that targeting Shp2 may 
provide a novel therapeutic option for treating FLT3-ITD-positive AML patients.  
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CHAPTER FOUR 
GENETIC DISRUPTION OF SHP2 INHIBITS FLT3-ITD-INDUCED 
HYPERPROLIFERATION AND PERMITS LONG TERM SURVIVAL OF ANIMALS 
TRANSPLANTED WITH N51-FLT3-ITD-EXPRESSING CELLS 
Introduction 
 
To understand the molecular mechanism of FLT3-ITD-induced leukemogenesis, 
cell lines bear substantial limitations.  Studies using heterologous cell lines provide useful 
mechanistic and functional information; however, their use is limited as cell lines are 
commonly transformed and may not entirely reflect the signaling mechanisms of primary 
leukemic cells.  Therefore, in addition to using cell lines, we have utilized a retroviral 
transduction method to introduce FLT3-ITD constructs into primary murine bone marrow 
cells, complimenting and validating our findings using the FLT3-ITD-expressing Baf3 
cells.  These primary cell studies will provide a working model of FLT3-ITD-induced 
leukemogenesis, but moreover, set up the foundation to use an in vivo mouse model 
system.  Based on our initial studies in the Baf3 and MV411 cells, we hypothesized the 
genetic disruption of Shp2 in primary murine bone marrow cells would reduce FLT3-
ITD-induced hyperproliferation, STAT5 hyperactivation, and leukemia progression in 
vivo. 
For our in vitro studies, we used a murine retroviral transduction system to infect 
primary C57BL/6 low density mononuclear cells (LDMNCs) with empty vector 
(pMSCV), WT-FLT3, or N51-FLT3.  One of the main benefits of this system is the 
retroviral vector is bicistronic expressing our gene of interest, FLT3, as well as enhanced 
green fluorescent protein (EGFP).  This allows us to use flow cytometry to enrich for 
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EGFP+, FLT3-expressing cells.  Sorted, EGFP+ cells can subsequently be used for in 
vitro experiments to complement our BaF3 studies, as well as set up the working model 
using primary cells and eventually in vivo studies.   
We are interested in the role of Shp2 in the bone marrow in the presence of FLT3-
ITD-induced leukemic progression and leukemogenesis.  In order to understand how 
Shp2 functions in the context of FLT3-ITDs, we must first consider its role in normal 
hematopoiesis.  Shp2 has been shown to be important for normal embryonic stem cell 
differentiation (Chan, Johnson et al. 2003); when Shp2 is not fully functional, there is a 
block in normal ES cell differentiation which retains the ES cells in the undifferentiated, 
stem cell compartment.  Shp2 is also essential for hematopoietic stem cell (HSC) self-
renewal, as Shp2+/- HSC have reduced self-renewal in serial transplants (Chan, Li et al. 
2006).  Therefore, Shp2 is important in stem cell differentiation and self-renewal which 
leads us to question what happens in the absence of Shp2 when another oncogene, such 
as N51-FLT3 is also present in the bone marrow?   
Homozygous knock out of murine Shp2 results in embryonic lethality during mid-
gestation (Saxton, Henkemeyer et al. 1997).  Therefore, these Shp2 knockout mice cannot 
be studied.  To combat this problem however, Gen-Sheng Feng and his lab developed a 
conditional Shp2 knockout animal (Zhang, Chapeau et al. 2004).  Two loxP sites were 
introduced in introns flanking exon 4 of the Shp2 allele.  Cre-induced recombination 
results in deletion of exon 4, insertion of a frameshift mutation and generation of a stop 
codon rendering the Shp2 protein non-functional (Zhang, Chapeau et al. 2004).  These 
animals can be subsequently bred to other transgenic animals which express promoter-
specific Cre recombinase.  For example, Zhang and colleagues crossed Shp2flox/flox mice 
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with CaMKIIα-Cre transgenic animals in order to study the role of Shp2 knockout in 
adult brain tissue (Zhang, Chapeau et al. 2004).   
We had the opportunity to use this Shp2flox/flox mouse model in order to investigate 
the role of Shp2 in N51-FLT3-induced leukemogenesis.  In order to knock out Shp2 in 
the bone marrow, we crossed Gen-Sheng Feng’s Shp2flox/flox animals with Mx1-Cre-
positive (Mx1-Cre+) transgenic animals (Kuhn, Schwenk et al. 1995) to generate Mx1-
Cre+;Shp2flox/flox and Mx1-Cre-;Shp2flox/flox animals.  Upon intraperitoneal injection of 
polyI/polyC, Cre recombinase is activated and Shp2 is deleted in the hematopoietic 
compartment of Mx1-Cre+ animals.  Mx1-Cre is expressed in hematopoietic tissues, 
liver, spleen, and duodenum; but is also expressed, to a lesser degree in other tissues such 
as heart, lung, and kidney (Kuhn, Schwenk et al. 1995).  Using LDMNCs from 
polyI/polyC treated Mx1-Cre+;Shp2flox/flox and Mx1-Cre-;Shp2flox/flox animals, we are able 
to test the effects of loss of Shp2 on N51-FLT3-induced hyperproliferation and 
hyperactivation of STAT5 in vitro.  
As mentioned, the activation of STAT5 is one of the most obvious and aberrantly 
activated signals in FLT3-ITD signaling; therefore; we are interested in how FLT3-ITDs 
can work with activated STAT5 to induce leukemogenesis.  Interestingly, Moore and 
colleagues demonstrated that expressing either N51-FLT3 or a constitutively active 
mutant of STAT5 in human cord blood CD34+ cells both increase the self-renewal 
capabilities of these cells (Schuringa, Chung et al. 2004; Chung, Morrone et al. 2005).  
Even though these examples are in human cord blood, these data suggest that FLT3-ITD 
and/or hyperactive STAT5 contribute to increased HSC self-renewal, which may 
contribute to the pathogenesis and progression of leukemia.   
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In addition to in vitro experiments, we chose to test the role of Shp2 in FLT3-
ITD-induced leukemia in vivo.  It was previously reported that male, BALB/c, 5-
fluorouracil (5FU)-treated bone marrow cells infected with N51-FLT3 transplanted into 
lethally irradiated female BALB/c recipient mice succumb to myeloproliferative disorder 
(MPD) quite rapidly with an average latency between 40 and 60 days (Rocnik, Okabe et 
al. 2006).  However, our Shp2flox/flox animals are backcrossed onto a C57BL/6 
background; therefore, we first needed to test if N51-FLT3 was able to induce MPD in 
the C57BL/6 genetic background in order to set up the model system. 
Once we established a N51-FLT3-induced MPD model in the C57Bl/6 
background, we next investigated the effect of Shp2 deletion in vivo by transplanting 
lethally irradiated recipients with N51-FLT3-transduced bone marrow low density 
mononuclear cells (LDMNCs) from Mx1-Cre+;Shp2flox/flox or Mx1-Cre-;Shp2flox/flox 
animals.  After allowing the cells to engraft, polyI/polyC was used to induce Cre-
recombination, deleting Shp2 in the bone marrow.  Using this model, we have been able 
to test the effects of loss of Shp2 on N51-FLT3-induced leukemogenesis in vivo.  Since 
bone marrow Shp2-/- cells have decreased self-renewal, but N51-FLT3- and 
constitutively activated STAT5-expressing cord blood cells have increased self-renewal, 
we were able to answer the question of whether or not Shp2 deletion reduces HSC 
function even in the presence of oncogenic N51-FLT3.  We therefore hypothesize that 
hematopoietic-specific loss of Shp2 in the presence of N51-FLT3 will result in either an 
increase in latency to or prevention of N51-FLT3-induced malignancy all together.   
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Results 
N51-FLT3 Induces Hyperproliferation of Primary Murine Low Density Bone Marrow 
Cells 
To examine the effect of FLT3-ITDs on cellular proliferation and signaling, we 
utilized murine bone marrow LDMNCs transduced with N51-FLT3.  We hypothesized 
that primary murine bone marrow progenitors expressing N51-FLT3 would be 
hyperproliferative and have hyperactivated signaling molecules compared to primary 
murine bone marrow progenitors expressing WT-FLT3.  Murine LDMNCs were isolated 
by Ficoll gradient and transduced with retroviral supernatants containing pMSCV, 
pMSCV-WT-FLT3, and pMSCV-N51-FLT3.  The pMSCV plasmids are bicistronic 
expressing the indicated FLT3 cDNA in addition to enhanced green fluorescent protein 
(EGFP).  Transduced cells were sorted for EGFP expression (Figure 4.1A), and were 
subsequently used for proliferation and biochemical studies.   
Thymidine incorporation assays were used to measure proliferation of the 
transduced cells (Figure 4.1B).  Sorted EGFP+ cells were cultured overnight followed by 
starvation in 0.2% BSA in IMDM for 5 hours.  Cells were then counted and plated into 
thymidine incorporation assays in the absence (baseline) or presence of 100 ng/ml FL, as 
previously described.  These studies demonstrate that cells transduced with MSCV, or 
WT-FLT3 are fairly quiescent at baseline conditions and proliferate in response to FL-
stimulation.  Likely MSCV is responsive to FL because of low levels of endogenous 
FLT3 expression in the LDMNc.  Cells transduced with N51-FLT3 however, displayed 
constitutive hyperproliferation at baseline similar to that observed with Baf3/N51-FLT3 
and Baf3/N73-FLT3 and are slightly more proliferative upon FL-stimulation compared to 
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WT-FLT3.  Baf3/N51-FLT3 cells are likely modestly induced by FL, because FL-
stimulation elicits activation of endogenous WT FLT3 receptors resulting in increased 
proliferation.           
A portion of EGFP-positive sorted cells were cultured into macrophage 
progenitors and used to make total protein lysates to examine FLT3 levels.  Briefly, 
macrophage progenitors were starved overnight in serum-free IMDM and collected 
(baseline) or stimulated with 100ng/ml FL for 5 minutes.  Total protein lysates were 
analyzed by immunoblot analysis and demonstrated similar FLT3 protein expression in 
both WT-FLT3 and N51-FLT3 transduced murine progenitors (Figure 4.1C).  This 
suggests that the hyperproliferation exhibited by N51-FLT3 is due to the mutation itself 
and not merely due to overexpression of FLT3.   
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Figure 4.1:  N51-FLT3 induces hyperproliferation in murine low density 
mononuclear cells 
 
(A) FACS analysis was used to sort and collect murine LDMNCs transduced with MSCV 
(empty vector), WT-FLT3, or N51-FLT3.  (B) Representative data of 3 independent 
experiments; 3H thymidine incorporation of MSCV-, WT-FLT3-, and N51-FLT3-
transduced LDMNCs; n = 3; statistics generated by unpaired, two-tailed, T-test.  (C) 
FLT3 protein expression in WT- and N51-FLT3 expressing cells as demonstrated by 
western blot analysis.   
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N51-FLT3 exhibits hyperactivation of STAT5 
We illustrated that N51-FLT3 induced a hyperproliferative phenotype in primary 
murine bone marrow cells, similar to that observed in the Baf3 cells.  We next 
investigated the activation of signaling molecules STAT5 and Erk in primary murine 
N51-FLT3-expressing cells.  Sorted WT-FLT3- and N51-FLT3-transduced primary bone 
marrow cells were cultured in M-CSF (50ng/ml)-containing media for one week to 
generate macrophage progenitors.  Cells were starved overnight in IMDM and then total 
cell lysates were prepared at baseline or after FL-stimulation (100ng/ml) for 5, 10, or 30 
minutes.  Immunoblot analysis (Figure 4.2) revealed similar FLT3 expression in both 
WT-FLT3 and N51-FLT3 transduced cells.  Interestingly, the unglycosylated, immature 
form of FLT3 (lower band) is the predominant form in the N51-FLT3-expressing cells 
compared to the glycosylated, mature form (upper band) in the WT-FLT3-containing 
cells (Figure 3.2).  This observation has been reported previously, and is thought to be 
due to retention of immature, relatively unglycosylated FLT3-ITD in the endoplasmic 
reticulum and/or golgi apparatus (Schmidt-Arras, Bohmer et al. 2005; Koch, Jacobi et al. 
2008).  Consistent with this, through collaboration with Dr. XingJun Li, we have shown 
preliminary data that there is co-localization between FLT3 and golgi, as well as Shp2 
and golgi in FLT3-ITD+ cells compared to FLT3-ITD- cells (data not shown), therefore 
one possible mechanism is that Shp2 interacts with FLT3-ITD in the golgi.  As 
anticipated, STAT5 was constitutively activated by N51-FLT3 independent of FL-
stimulation while STAT5 activation was undetectable in WT-FLT3-transduced cells 
(Figure 4.2).  We observed Erk activation to be robustly induced by FL in both WT- and 
N51-FLT3 expressing cells.  At the 5-minute time point however, phospho-Erk appeared 
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higher in the WT-FLT3-expressing cells.  We have seen this phenomenon on several 
occasions and suspect that the mature, membrane-bound FLT3 (which is more heavily 
expressed in WT-FLT3-expressing cells than N51-FLT3-expressing cells) signals more 
efficiently to Erk, which is commonly an out-put of traditional Shp2 activity, while the 
immature, endoplasmic reticulum or golgi-bound FLT3 (predominant in N51-FLT3-
expressing cells) signals primarily to STAT5, which is consistent with the findings of 
others (Choudhary, Olsen et al. 2009; Schmidt-Arras, Bohmer et al. 2009).  Phospho-
STAT5 participates in the activation of transcriptional targets, especially pro-leukemic 
proteins such as Bcl-XL and Cyclin-D1 which are often upregulated in cancer.  
Collectively, these findings indicate that we are able to induce FL-independent 
hyperproliferation and STAT5 hyperphosphorylation using the retroviral vector, MSCV-
N51-FLT3, permitting us to examine the contribution of various molecular mechanisms 
to FLT3-ITD-induced leukemogenesis.     
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Figure 4.2:  Western blot analysis of primary bone marrow transduced with WT- or 
N51-FLT3   
 
Whole cell lysates from WT-FLT3- and N51-FLT3-transduced macrophage progenitors 
were subjected to immunoblot analysis and probed with α-FLT3, α-GAPDH, α-phospho-
STAT5 (P-STAT5), α-total-STAT5 (T-STAT5), α-phospho-Erk (P-Erk), or α-total-Erk 
(T-Erk) antibodies.   
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Conditional Shp2 knockout mouse model 
As mentioned previously, Gen-Sheng Feng and his lab created a Shp2flox/flox 
mouse model which he graciously shared with us.  Shp2flox/flox animals were crossed with 
Mx1-Cre+ animals to result in heterozygous Shp2flox/+;Mx1-Cre+ and Shp2flox/+;Mx1-
Cre- progeny.  Heterozygous animals were subsequently mated to yield Shp2flox/flox;Mx1-
Cre+ and Shp2flox/flox;Mx1-Cre- animals.  To induce Cre recombinase expression, 300µg 
of polyI/polyC was injected intraperitoneally on days 1, 3, and 5 into 4-6 week old 
animals.  Two to six weeks post polyI/polyC treatment, LDMNCs were isolated and 
transduced with either WT-FLT3 or N51-FLT3, sorted, and used in thymidine 
incorporation assays or by FACS analysis of phospho-STAT5 (Figure 4.3). 
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Figure 4.3:  Schematic representation of Shp2flox/flox; Mx1-Cre+ and Shp2flox/flox; 
Mx1-Cre- animals and their use for in vitro functional and biochemical studies 
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To measure Shp2 recombination and generation of the recombined Shp2-null 
allele, we performed the following experiment.  Two to six weeks post polyI/polyC 
treatment, Shp2flox/flox;Mx1-Cre+ and Shp2flox/flox;Mx1-Cre- mice were sacrificed and 
tissues harvested.  Genomic DNA was extracted from tail and bone marrow samples of 
the polyI/polyC-treated Shp2flox/flox;Mx1-Cre- and Shp2flox/flox;Mx1-Cre+ mice and total 
protein lysates were produced from a portion of the bone marrow of the same mice.  
Using primers that amplify the WT-Shp2 allele, Shp2-floxed, and recombined Shp2 
(Shp2-null) allele, PCR amplification is shown in Figure 4.4.  DNA from tail and bone 
marrow (BM) from polyI/polyC-treated Shp2flox/flox;Mx1-Cre- animals as well as DNA 
derived from the tail of polyI/polyC-treated Shp2flox/flox;Mx1-Cre+ animals contains only 
the Shp2-floxed allele and do not have any detectable Shp2-null allele.  However, DNA 
from the BM of Shp2flox/flox;Mx1-Cre+ animals demonstrates a clear recombination of the 
Shp2-Flox allele, yielding the Shp2-null allele (Figure 4.4A).  Similarly there was a 
significant reduction in Shp2 protein expression in total protein lysates from the BM of 
polyI/polyC-treated Shp2flox/flox;Mx1-Cre+ animals compared to that of polyI/polyC-
treated Shp2flox/flox;Mx1-Cre- mice (Figure 4.4B).  Recombination of Shp2 at the DNA 
level as well as reduction of Shp2 protein levels indicates that in this system, polyI/poyC 
treatment is sufficient to reduce Shp2 DNA and protein in the BM of Shp2flox/flox;Mx1-
Cre+ animals suggesting that this animal model is suitable to test the loss of Shp2 on 
N51-FLT3-induced hyperproliferation and hyperactivation of STAT5. 
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Figure 4.4:  Shp2 DNA 
recombination and protein 
deletion after PolyI/polyC 
treatment 
    
(A) Polymerase chain reaction (PCR) 
amplifying the floxed Shp2 allele as 
well as the recombined, null allele of 
DNA from tail and bone marrow 
cells from polyI/polyC treated 
Shp2flox/flox;Mx1-Cre- (Mx1 Cre-) 
and Shp2flox/flox;Mx1-Cre+ (Mx1 
Cre+) animals.  (B) Immunoblot 
analysis of Shp2 protein levels of the 
bone marrow from Shp2flox/flox;Mx1-
Cre- (Mx1Cre-), or Shp2flox/flox;Mx1-
Cre+ (Mx1Cre+) mice. 
 
 
After demonstrating successful recombination by polyI/polyC treatment, LDMNCs 
of polyI/polyC-treated Shp2flox/flox;Mx1-Cre- and Shp2flox/flox;Mx1-Cre+ cells were 
isolated and transduced with either WT-FLT3 or N51-FLT3.  Transduced cells were then 
sorted on EGFP expression and collected.  Transduction efficiencies are similar between 
the 4 cell types (Figure 4.5A).  Additionally, a small portion of EGFP+ cells were lysed 
and total cell protein lysates were made and subjected to immunoblot analysis.  The 4 
sorted cell populations demonstrated similar total FLT3 expression, as well as total Erk 
(control) expression (Figure 4.5B).  This suggests that WT-FLT3- or N51-FLT3-
expressing Shp2flox/flox;Mx1-Cre- and WT-FLT3- or N51-FLT3-expressing 
Shp2flox/flox;Mx1-Cre+ cells can be transduced to express similar levels of FLT3, and can 
therefore be subsequently compared to one another to understand the effects of loss of 
Shp2 on N51-FLT3-induced transformation. 
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Figure 4.5:  Transduction efficiency and FLT3 expression of WT-FLT3 or N51-
FLT3 transduced Shp2flox/flox;Mx1-Cre- or Shp2flox/flox;Mx1-Cre+ cells 
 
(A) WT-FLT3- or N51-FLT3-transduced Shp2flox/flox;Mx1-Cre- and Shp2flox/flox;Mx1-
Cre+  were sorted using FACS.  (B) Equal amounts of protein lysates from WT-FLT3 or 
N51-FLT3 expressing Shp2flox/flox;Mx1-Cre- cells and WT-FLT3 or N51-FLT3 
expressing Shp2flox/flox;Mx1-Cre+ cells were subjected to SDS-Page gel electrophoresis 
and probed with α-FLT3 or α-T-Erk.   
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Genetic knockout of Shp2 in vitro results in reduced hyperproliferation induced by 
N51-FLT3 
In order to investigate the loss of Shp2 on N51-FLT3-induced cellular 
hyperproliferation, polyI/polyC-treated Shp2flox/flox;Mx1-Cre+ and Shp2flox/flox;Mx1-Cre- 
LDMNCs were transduced with either WT-FLT3 or N51-FLT3 retroviral supernatant and 
EGFP+ cells sorted and collected.  EGFP+ cells were then cultured overnight in 
prestimulation media.  The following day, cells were starved in 0.2% BSA-IMDM for 4-5 
hours, as previously described, and plated into thymidine incorporation assays in the 
absence (baseline) or presence of 100ng/ml FL.  WT-FLT3-expressing Shp2flox/flox;Mx1-
Cre- cells proliferate upon FL stimulation and their proliferation is similar to that 
compared to polyI/polyC-treated Shp2flox/flox;Mx1-Cre+ cells (Figure 4.6).  N51-FLT3-
expressing Shp2flox/flox;Mx1-Cre- cells are hyperproliferative at baseline and upon FL-
stimulation (Figure 4.6).  However, this hyperproliferation is significantly decreased at 
baseline and upon FL-stimulation in N51-FLT3-expressing polyI/polyC-treated 
Shp2flox/flox;Mx1-Cre+ cells.  These data suggest that without Shp2, the ability for N51-
FLT3 to induce cellular hyperproliferation is compromised and that Shp2 in part 
contributes to the hyperproliferative phenotype exhibited by N51-FLT3-expressing cells.   
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Figure 4.6:  Loss of Shp2 significantly reduces N51-FLT3 hyperproliferation in vitro 
 
 3H-tritiated thymidine incorporation assays comparing WT-FLT3- or N51-FLT3-
expressing Shp2flox/flox;Mx1-Cre- (WT levels of Shp2) to WT-FLT3- or N51-FLT3-
expressing Shp2flox/flox;Mx1-Cre+ (Shp2 knockout cells) at baseline and in response to 
FL-stimulation are shown.  Data presented is the combination of 2 independent 
experiments (n = 4 in 2 independent experiments).  Statistical analysis performed using 
random effects ANOVA. 
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In vitro knockout of Shp2 results in reduced N51-FLT3-induced activation of STAT5 
As previously stated, aberrant activation of STAT5 is one of the hallmarks of 
FLT3-ITD-induced signaling.  In order to examine N51-FLT3-induced hyperactivation of 
STAT5 in the absence of Shp2, we made total cell protein lysates from WT-FLT3- or 
N51-FLT3-transduced polyI/polyC-treated Shp2flox/flox;Mx1-Cre- or Shp2flox/flox;Mx1-
Cre+ cells and subjected them to immunoblot analysis.  Similar to previous experiments 
with primary cells, STAT5 activation is undetectable in WT-FLT3-expressing cells 
regardless of the Shp2 level (Figure 4.7).  N51-FLT3-expressing cells demonstrate high 
levels of phospho-STAT5 with WT Shp2 levels (Shp2flox/flox;Mx1-Cre- cell extracts), but 
levels are reduced by 1.78 fold when Shp2 is deleted (polyI/polyC-treated 
Shp2flox/flox;Mx1-Cre+ cell extracts) (Figure 4.7).  When blotting for total Shp2 levels, we 
observed a significant reduction in both the WT-FLT3- and N51-FLT3-transduced 
Shp2flox/flox;Mx1-Cre+ cell extracts; however, we noted that the degree of Shp2 reduction 
was different between WT-FLT3-expressing Cre+ cell extracts and N51-FLT3-
expressing Cre+ cell extracts (Figure 4.7).  We speculate that the rapidly proliferating 
N51-FLT3-expressing cells, especially those with residual Shp2 protein, are able to 
proliferate quite quickly, outgrowing some of the Shp2-/- cells.  Ultimately the reduction 
in Shp2 is much more significant in WT-FLT3-expressing cell lysates.  However, it is 
notable that only a 20% (1.2-fold) reduction of Shp2 results in a 46% (1.78-fold) 
reduction in P-STAT5, indicating that even a modest reduction of Shp2 levels 
significantly reduces phospho-STAT5 levels in the N51-FLT3-expressing cells. 
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Figure 4.7:  Genetic disruption of Shp2 results in a significant reduction of P-
STAT5 induced by N51-FLT3 measured by immunoblot analysis 
 
Sorted, EGFP+ WT-FLT3- or N51-FLT3 expressing Shp2flox/flox;Mx1-Cre- and 
Shp2flox/flox;Mx1-Cre+ cells were cultured overnight in prestimulation media (containing 
100ng/ml SCF, TPO, and G-CSF).  The following morning total cell lysates were 
prepared and run on SDS-Page gels.  Membranes were probed with α-phospho STAT5 
(P-STAT5), α-total STAT5 (T-STAT5), and α-total Shp2 (T-Shp2).  Relative quantity 
was measured using the BIO-RAD Chemidoc imager and is indicated as the percent 
expression compared to N51-FLT3, Shp2flox/flox;Mx1-Cre- samples.    
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To test the P-STAT5 levels by a second means, WT-FLT3- or N51-FLT3- 
expressing Cre- or Cre+ cells were stained intracellularly with α-P-STAT5-APC or APC 
mouse IgG1 isotype and analyzed by flow cytometry.  Figure 4.8A displays the 
scatterplots from FACS analysis of the four cell populations.  Both WT-FLT3-expressing 
Shp2flox/flox;Mx1-Cre- and Shp2flox/flox;Mx1-Cre+ demonstrate negligible amounts of P-
STAT5 as detected by flow cytometry, similar to that observed using immunoblot.  As 
expected, N51-FLT3-expressing Shp2flox/flox;Mx1-Cre- cells highly activated STAT5, 
with 44% of the cells positive for P-STAT5 staining (Figure 4.8A).  However, upon Shp2 
deletion in the N51-FLT3-expressing Shp2flox/flox;Mx1-Cre+ cells, there was a 1.7-fold 
reduction of STAT5 activation (26%), very similar to that observed using 
immunoblotting.  This flow cytometry data in the N51-FLT3-expressing cells is 
highlighted in the histogram in Figure 4.8B, where there is an obvious shift to the left in 
P-STAT5 immunofluorescence levels when Shp2 protein expression is reduced.  This 
data nicely complements the immunoblot data in Figure 4.7, as the changes in P-STAT5 
percentages are nearly identical between the two types of experiments, providing further 
data that N51-FLT3-expressing cells rely heavily on Shp2 to activate STAT5.   
 
Overall, the Shp2flox/flox;Mx1-Cre mouse model provides a useful model system in 
vitro where we are able to use Shp2-null bone marrow cells to demonstrate that reduced 
Shp2 levels result in a significant reduction in N51-FLT3-induced cellular 
hyperproliferation and STAT5 activation, which nicely correlates with the data presented 
in Chapter Three using Baf3 cells and shRNAs targeted to Shp2.  To further investigate 
this role of Shp2 on N51-FLT3-induced MPD, we will next use the mouse model in vivo 
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to knock out Shp2 in a N51-FLT3-transplant recipient mouse to determine if the loss of 
Shp2 in the bone marrow will prevent N51-FLT3-induced MPD.
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Figure 4.8:  Genetic disruption of Shp2 results in a significant reduction of P-
STAT5 induced by N51-FLT3 as measured by flow cytometry 
 
A portion of the previously described sorted, EGFP+ WT-FLT3- or N51-FLT3-
transduced Cre- or Cre+ cells were stained with α-P-STAT5-APC or the corresponding 
isotype.  Cells were analyzed by FACS and the P-STAT5-APC positive populations 
measured.  Data is presented in scatterplots (A) and summarized in histogram (B). 
A
 
B
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Establishing a FLT3-ITD+ C57BL/6 mouse model 
We have demonstrated that loss of Shp2 significantly reduces the proliferation 
and the aberrant activation of STAT5 induced by N51-FLT3 in vitro using both cell line 
and primary cell models.  In order to test the leukemic potential of N51-FLT3 in the 
absence of Shp2 in vivo, we proposed to transplant lethally irradiated recipient mice with 
WT-FLT3 or N51-FLT3-transduced Shp2flox/flox;Mx1-Cre- or Shp2flox/flox;Mx1-Cre+ 
LDMNCs followed by treatment with polyI/polyC to delete Shp2 expression.  These 
recipient animals would provide a useful model system to test the effects of Shp2 
knockout on the leukemic potential of N51-FLT3 in vivo.    
Given that previous transplant models of N51-FLT3-induced MPD in vivo 
utilized BalbC mice (Kelly, Liu et al. 2002), we needed to establish an effective model on 
the murine, C57Bl/6 background.  In order to investigate N51-FLT3-induced MPD on a 
C57BL/6 background, we set up our in vivo experiment as depicted in Figure 4.9.  
Briefly, 3 Shp2flox/flox;Mx1-Cre- C57BL/6 mice (CD45.2 positive) were injected with 150 
mg/kg 5-fluorouracil (5-FU) to enrich for primitive progenitors and hematopoietic stem 
cells (HSCs).  Three days later, mice were euthanized and LDMNCs were isolated and 
plated into prestimulation media overnight.  After two rounds of retroviral transductions, 
cells were sorted on EGFP positivity and resuspended in 0.05% endotoxin-free BSA-
IMDM at a concentration of 1 million EGFP+ cells plus 100,000 supporting low density 
mononuclear supporting splenocytes in 300µl volume.  The splenocytes contain more 
mature progenitors which act to supplement the recipient animals’ immune system while 
the immature, stem cell and progenitor donor cells have time to engraft and fully 
reconstitute the bone marrow.  Cells were administered via tail vein injection into 7 
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lethally irradiated F1 (C57/BoyJ F1) recipients (CD45.1/CD45.2 double positive). The 
advantage of transplanting C57BL/6 mice into F1 recipients is that the donor, C57BL/6 
animals are single positive for CD45.2, while the F1 recipients are CD45.1/CD45.2 
double positive, therefore we are able to use flow cytometry to determine the percentage 
of cells that came from the donor animals and the percentage of cells from the recipient 
host.      
 
 
Figure 4.9:  Schematic representation N51-FLT3-induced MPD in vivo on a C57Bl/6 
background 
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Tail vein bleeds were performed at 5 and 10 weeks post-transplant.  Using the 
peripheral blood, complete blood counts (cbc) were assessed to determine the number of 
white blood cells.  The samples were then subjected to red blood cell lysis buffer to 
remove the majority of erythrocytes followed by staining with α-CD45.1-phycoerythrin 
(PE) and α-CD45.2-allophycocyanin (APC).  Flow cytometry was used to analyze the 
percentage of blood cells which were EGFP-positive, suggesting that they were N51-
FLT3-expressing donor cells and to analyze the percentage of blood cells which were 
donor-derived (CD45.2-APC+), or residual recipient cells (CD45.1-PE/CD45.2-APC 
double positive).  Figure 4.10A demonstrates the average percentage of EGFP+ cells, 
average number of white blood cells (WBCs, measured in thousands), and the average 
percentage of donor-derived CD45.2-APC+ cells.  We observed an obvious trend that the 
EGFP+ and CD45.2+ donor-derived cell populations increased between 5 and 10 weeks 
post-transplant (Figure 4.10A).  While the average number of white blood cells increased 
slightly, the increase was less apparent.  However, consistent with increasing EGFP+ 
cells, we found that several of the N51-FLT3-transplanted recipients developed MPD 
between 10-14 weeks post-transplant as demonstrated by the survival curve of this cohort 
of animals (Figure 4.11). A spleen from a representative N51-FLT3-transplant recipient 
is shown demonstrating splenomegaly with a length of approximately twice that of a wild 
type mouse (Figure 4.10B).  Upon hematoxalin and eosin (H&E) staining of cross 
sections of the spleens, we observed significant disruption of the splenic architecture by 
N51-FLT3 indicative of MPD (Figure 4.10C).  This pilot study demonstrated that N51-
FLT3-induced MPD in C57BL/6 animals is feasible, permitting us to proceed with 
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studies in the Shp2flox/flox;Mx1Cre+  mouse model of MPD to test the effect of Shp2 loss 
on N51-FLT3-induced leukemogenesis. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10:  N51-FLT3-induced MPD on a C57Bl/6 background 
 
(A) Percent EGFP+, white blood cells number (thousands), and percent donor cells 
(CD45.2+) are displayed as the average of the transplant recipients 5 weeks (7 animals) 
and 10 weeks (6 animals) post-transplant.  Whole spleen (B) and H&E staining of a cross 
section (C) of a wildtype mouse compared to a representative N51-FLT3-transplant 
recipient.  
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Figure 4.11:  Survival curve of N51-FLT3-transplant recipients on C57Bl/6 
background 
 
Shp2flox/flox;Mx1-Cre- cells transduced with N51-FLT3 and transplanted into lethally 
irradiated recipients.  Survival curve represents the percent living animals at a given time 
point post-transplant, n = 7. 
 
 
Loss of Shp2 expression in a N51-FLT3+ mouse model 
In setting up the N51-FLT3-transduced, Shp2flox/flox;Mx1-Cre+ animal transplant 
model in order to test the loss of Shp2 on N51-FLT3-induced leukemogenesis, we 
encountered a serious challenge.  Unfortunately, 5-FU treatment of Shp2flox/flox;Mx1-Cre+ 
animals resulted in substantial cell death of bone marrow cells, presumably because 
Shp2-decficnet cells are less quiescent than wild type controls (Chan, Li et al. 2006; 
Chan, Cheung et al. 2011; Zhu, Ji et al. 2011).  Therefore, 5-FU treatment of Shp2flox/flox 
Mx1-Cre+ animals resulted in significantly reduced cell numbers; insufficient for 
retroviral transduction and subsequent transplantation of Shp2flox/flox;Mx1-Cre+ cells into 
84 
 
recipient animals which presented us with a serious problem in our proposed transplant 
study.   
To speculate on this problem, we have found that there is breakthrough Mx1 
promoter-directed Cre expression even without polyI/polyC treatment which contributes 
to low levels of Shp2 recombination and a baseline reduced Shp2 expression.  Therefore, 
baseline reduced Shp2 levels may have caused the bone marrow cells in the 
Shp2flox/flox;Mx1-Cre+ animals to be much more sensitive to 5-FU treatment compared to 
the Shp2flox/flox;Mx1-Cre- animals.  Furthermore, the 5-FU treatment itself may have 
induced a cytokine release resulting in unwanted enhanced Mx1 promoter-directed Cre 
expression in the Shp2flox/flox;Mx1-Cre+ animals, leading to further reduction in Shp2 
expression which resulted in death of bone marrow cells.  To overcome this problem, we 
utilized a lineage depletion kit from StemCell Technologies to isolate the most immature 
and stem cell-like progenitors from the bone marrow LDMNCs from both the 
Shp2flox/flox;Mx1-Cre- Shp2flox/flox;Mx1-Cre+ animals for all subsequent experiments.  
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Figure 4.12:  Schematic representation of WT-FLT3- or N51-FLT3-transduced-
Shp2flox/flox;Mx1-Cre- and Shp2flox/flox;Mx1-Cre+ transplants 
 
General outline of the experimental design is shown beginning with harvesting the bone 
marrow LDMNCs, transduction, transplant, monitoring, and division into polyI/polyC or 
PBS treatment groups.  Diagram represents the combination of animals used in 3 
independent experiments with expected outcomes indicated. 
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The overall scheme of the transplant experiments is highlighted in Figure 4.12.  
Shp2flox/flox;Mx1-Cre- and Shp2flox/flox;Mx1-Cre+ animals were sacrificed and bone 
marrow LDMNCs isolated and subjected to lineage depletion.  A small amount of cells 
(both pre and post lineage depletion) were stained with a cocktail of lineage markers 
including Gr-1, Mac-1, B220, Ter119, CD-3, and CD-8.  Prior to lineage depletion, 3.6% 
of Cre- and 5.8% of Cre+ cells were lineage negative, after lineage negative isolation, 
Cre- cells were 54% and Cre+ cell were 65.6% lineage negative (Figure 4.13A).  These 
lineage-negative LDMNCs were transduced with either pMSCV-WT-FLT3 or pMSCV-
N51-FLT3 retroviral supernatants on days 3 and 4, and then plated into prestimulation 
media until sorted on EGFP expression.  Shp2flox/flox;Mx1-Cre- cells had similar 
transduction efficiencies of either 41.3% EGFP+  in Cre-, WT-FLT3-expressing cells or 
47% EGFP+ in Cre-, N51-FLT3-expressing cells (Figure 4.13B).  On the other hand, the 
transduction efficiencies of the Cre+ cells were significantly lower, 15% for Cre+, WT-
FLT3 and 21% EGFP+ for Cre+, N51-FLT3 (Figure 4.13B).  Interestingly, we often 
observed a similar difference in transduction efficiencies between Cre- and Cre+ cells.  
We suspect that breakthrough Cre expression leads to a slight reduction in Shp2 levels 
and these cells do not divide as rapidly, therefore are not transduced as easily as the Cre- 
cells.  On the day of the transplant, 2 wild type F1 animals were sacrificed and spleen-
derived LDMNCs were isolated by ficoll gradient to provide radioprotective cells.  After 
the transduced cells were sorted, 1 million EGFP+ cells and 150,000 supporting 
splenocytes were mixed in 300µl total volume of 0.2% endotoxin-free BSM-IMDM and 
administered via tail vein injection.  Combining three independent experiments, we 
87 
 
transplanted the following animals followed by treatment with either phosphate buffered 
saline (PBS) or polyI/polyC:   
 
Table 4.1:  Number of transplant recipients, and treatment received post-transplant 
Genotype Number of Animals 
Shp2flox/floxMx1-Cre- WT-FLT3 7    (polyI/polyC treated) 
Shp2flox/floxMx1-Cre- N51-FLT3 16   polyI/polyC treated) 
Shp2flox/floxMx1-Cre+ WT-FLT3 7                (PBS treated) 
7   (polyI/polyC treated) 
Shp2flox/floxMx1-Cre+ N51-FLT3 20              (PBS treated) 
21  (polyI/polyC treated) 
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Figure 4.13:  Lineage depletion of bone marrow LDMNCs and sorting by 
fluorescence activated cell sorting (FACS)   
 
(A) Flow cytometry analysis demonstrating the enrichment in lineage negative 
populations of LDMNCs before and after Lineage depletion.  (B) FACS of transduced 
Shp2flox/flox;Mx1-Cre- and Shp2flox/flox;Mx1-Cre+ bone marrow Lin- cells with either WT-
FLT3 or N51-FLT3. 
A
 
B
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Animals transplanted with N51-FLT3-transduced cells demonstrate MPD and 
increased mortality compared to those transplanted with WT-FLT3-transduced cells 
We initially compared the survival of animals transplanted with N51-FLT3-
transduced cells to that of WT-FLT3-transduced cells, and found that similar to 
transplants utilizing bone marrow from 5-FU-treated Shp2flox/flox;Mx1Cre- animals, 
animals transplanted with N51-FLT3-transduced Shp2flox/flox;Mx1Cre- Lin- cells 
succumbed to MPD (Figure 4.14).  These animals were treated with polyI/polyC during 
the 5th week post-transplant.   
The Kaplan Meier curve demonstrated that the Cre-, WT-FLT3 recipients had an 
overall much longer survival compared to N51-FLT3 recipients (Figure 4.14).  While 
there were a couple of deaths in the WT-FLT3 transplant recipient group, we examined 
their spleen and bone marrow by H&E staining and consultation with pathologist, Dr. 
George Sandusky, Department of Pathology at Indiana University School of Medicine, 
and have concluded that these animals did not die of MPD or a leukemic phenotype.  
This data supports the idea that the presence of N51-FLT3 is truly leukemogenic in 
nature and WT-FLT3 alone is not sufficient to cause MPD in this mouse model. 
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Figure 4.14:  Overall Survival of animals transplanted with WT-FLT3- and N51-
FLT3-transduced Shp2flox/flox;Mx1Cre- Lin- cells 
 
Overall survival of Shp2flox/flox;Mx1-Cre- WT-FLT3 or N51-FLT3 transplant recipient 
mice.  Kaplan Meier estimation was calculated using ‘last day known alive (weeks)’.  n = 
7 for Cre-, WT-FLT3; n = 16 for Cre-, N51-FLT3; statistics generated by log-rank test. 
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Loss of Shp2 expression does not increase the overall survival of animals transplanted 
with N51-FLT3-transduced cells 
We were next interested to specifically determine if genetic reduction of Shp2 
would reduce the latency to or the severity of N51-FLT3-induced malignancy in vivo.  To 
perform these studies, four to six weeks after transplant, peripheral blood was evaluated 
from animals transplanted with N51-FLT3-transduced Shp2flox/flox;Mx1-Cre+ cells with 
complete blood counts for white blood cell counts and with flow cytometry for EGFP-
positive populations and CD45.2-APC-positive donor-derived populations.  Based on 
these data, animals were divided into 2 groups:  those to receive polyI/polyC, which we 
expect to induce Cre-recombinase expression and result in reduced Shp2 expression in 
the bone marrow, and those to receive PBS, which should maintain normal levels of Shp2 
expression.  The average chimerism (% 45.2+), EGFP expression, and white blood cell 
counts in the two N51-FLT3, Shp2flox/flox;Mx1-Cre+ groups prior to receiving 
polyI/polyC to induce Shp2 recombination or PBS as a vehicle control are displayed in 
Figure 4.15A-C, respectively.  Chimerism, EGFP, and white blood cell counts were 
similar comparing the two groups prior to treatment.  During week 5 post-transplant, 
animals were treated with either 300µg of polyI/polyC (150µl of 2mg/ml polyI/polyC) or 
150µl PBS as a control every other day for a total of 3 treatments.  Animals were 
monitored over time with subsequent tail bleeds to monitor white blood cell counts, 
chimerism, EGFP expression, and progression to MPD.  Upon death, animals were 
harvested, spleens weighed, and femurs and spleens sent to pathology for H&E staining 
to examine the tissues for evidence of malignancy.  We hypothesized that the 
polyI/polyC-treated N51-FLT3, Shp2flox/flox;Mx1-Cre+ transplant recipients would either 
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fail to develop MPD or have an increased latency to disease compared to PBS-treated 
N51-FLT3, Shp2flox/flox;Mx1-Cre+ transplants. 
The overall survival of the PBS-treated vs. polyI/polyC-treated Cre+ N51-FLT3 
animals is shown in Figure 4.15D.  We hypothesized that loss of Shp2 in the presence of 
N51-FLT3 would either increase the latency to disease, or prevent MPD entirely. As 
expected, a several polyI/polyC treated Cre+ N51-FLT3 animals did demonstrate 
prolonged survival, however, a few polyI/polyC-treated Cre+ N51-FLT3 animals died 
even earlier than PBS-treated Cre+ N51-FLT3 animals, therefore there is no significant 
difference in the overall survival of PBS-treated animals transplanted with Cre+ N51-
FLT3 compared to polyI/polyC-treated animals transplanted with Cre+ N51-FLT3 
(Figure 4.15D).   
93 
 
 
 
 
 
 
Figure 4.15:  Overall Survival of PBS-treated Cre+ N51-FLT3 vs pI/pC-treated 
Cre+ N51-FLT3 transplanted animals  
 
(A) Average chimerism (CD45.2%+), (B) percent EGFP+, and (C) white blood cell 
counts 4 weeks post-transplant of N51-FLT3-transduced Shp2flox/flox;Mx1Cre+ cells into 
lethally irradiated recipients (baseline), n = 21 for PBS group and n = 20 for polyI/polyC 
group.  (D) Kaplan Meier curve represents overall survival of PBS-treated Cre+ N51-
FLT3 (n = 18) vs. polyI/polyC-treated Cre+ N51-FLT3 (n = 17) transplanted animals 
with pathological diagnosis at time of death.   
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In order to fully understand why the polyI/polyC-treated animals experience early 
lethality, we examined the spleen and bone marrow histopathology and discovered that 
many of the polyI/polyC-treated animals transplanted with N51-FLT3-transduced 
Shp2flox/flox;Cre+ cells experienced early death due to profound bone marrow failure, 
examined with and confirmed by Dr. George Sandusky (Figure 4.16).  Compared to a 
wildtype bone marrow specimen (demonstrating a heterogeneous population of bone 
marrow cells with scant adipose pockets), a representative bone marrow failure specimen 
is shown and demonstrates severe hypocellularity and excessive adipose (Figure 4.16).  
The remaining bone marrow cells appeared stromal and fibroblast-like.  Normal splenic 
architecture is shown in the wildtype spleen sample with obvious white and red pulp.  
The spleen from the representative bone marrow failure specimen does have some visible 
red and white pulp, with evidence of extramedullary hematopoiesis (EMH).  EMH is a 
general term referring to hematopoiesis which occurs outside the bone marrow, and in 
these mice the splenic EMH is working to repopulate the animal’s hematopoietic system 
due to the deficiencies of the bone marrow.  Therefore, it seems that if Shp2 is knocked 
out too soon, or too completely, the animals succumb to bone marrow failure and death.  
However, we noted that some polyI/polyC-treated animals demonstrated prolonged 
survival compared to the PBS-treated Cre+ N51-FLT3 animals, therefore we next 
investigated the malignancy-specific survival.   
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Figure 4.16:  H&E staining of a polyI/polyC-treated Cre+ N51-FLT3 animal with 
bone marrow failure 
   
Bone marrow and spleen tissues from a wildtype mouse and from a representative 
polyI/polyC-treated Cre+ N51-FLT3 animal that died of bone marrow failure were 
sectioned and stained with H&E, shown at 50X and 100X magnification.   
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Loss of Shp2 increases the latency to and reduces the severity of malignancy in 
animals transplanted with N51-FLT3-transduced cells 
Although there was not a statistically significant difference in the overall survival 
of PBS-treated Cre+ N51-FLT3 treated animals vs. polyI/polyC-treated Cre+ N51-FLT3 
animals, we were interested to determine if genetic disruption of Shp2 was able to 
decrease the severity of or increase the latency to death specifically caused by 
malignancy.  Therefore, we consulted with Dr. George Sandusky, to review the 
histopathology of animals at the time of death.  For animals succumbing to malignancy, 
we found MPD (Figure 4.17i and ii), lymphoproliferative disorder (Figure 4.17iii), as 
well as a mixed myelo- and lymphoproliferative disorder (not shown).  Although several 
of the polyI/polyC-treated Cre+ N51-FLT3 animals did eventually develop leukemic 
disease, the average spleen weight of animals that died of confirmed leukemia were 
significantly smaller in the polyI/polyC-treated Cre+ N51-FLT3 group than the PBS-
treated Cre+ N51-FLT3 group (Figure 4.18A), implying a less severe and more indolent 
disease.  Futhermore, when evaluating survival in animals who specifically succumbed to 
malignancy, the Kaplan Meier survival curve for malignancy-specific survival of PBS-
treated Cre+ N51-FLT3 animals vs. polyI/polyC-treated Cre+ N51-FLT3 animals 
demonstrated a significantly prolonged survival in the polyI/polyC-treated Cre+ N51-
FLT3 animals compared to the PBS-treated Cre+ N51-FLT3 animals (Figure 4.18B).  
These data suggest that in our in vivo model of N51-FLT3-induced MPD, the absence of 
Shp2 results in an increased latency to and decreased severity of malignant disease.   
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Figure 4.17:  H&E staining of a representative N51-FLT3-induced hematologic 
malignancies 
  
Bone marrow and spleen sections from animals that died of myeloproliferative disease (i 
and ii) or lymphoproliferative disease (iii) were sectioned and stained with H&E, shown 
at 100X, 200X, and 400X magnification. 
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Figure 4.18:  Malignancy-specific survival of PBS-treated Cre+ N51-FLT3 vs pI/pC-
treated Cre+ N51-FLT3 transplanted animals 
 
(A) Average spleen sizes of PBS-treated N51-FLT3, Shp2flox/flox;Mx1-Cre+ animals (n = 
16) compared to polyI/polyC-treated N51-FLT3, Shp2flox/flox;Mx1-Cre+ animals (n = 10) 
that succumbed to malignancy, p<0.05, statistics performed using unpaired, two-tailed 
student’s t test.  (B)  Kaplan-Meier analysis of malignancy specific survival of mice 
transplanted with N51-FLT3-transduced Shp2flox/flox;Mx1Cre+ cells comparing PBS-
treated mice (control) to polyI:polyC-treated mice (genetic deletion of Shp2), n=16 in the 
PBS group and n=10 in the polyI;polyC group, p=0.024 by log-rank test.   
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Loss of Shp2 reduces the long term hematopoietic stem cell repopulating activity of 
N51-FLT3-transduced bone marrow cells 
Since we experienced a high proportion of polyI/polyC-treated Cre+ N51-FLT3 
animals that died from bone marrow failure, we examined the chimerism and EGFP+ 
populations in the animals in the PBS-treated vs. the polyI/polyC-treated animals 
transplanted with N51-FLT3-transduced Shp2flox/flox;Mx1Cre+ cells.  Comparing the 
average percentages of polyI/polyC-treated N51-FLT3-Cre+ cells to PBS-treated N51-
FLT3-Cre+ cells over time, there was a general decrease in the chimerism (percent donor 
cells) post-treatment in the polyI/polyC-treated N51-FLT3-Cre+ animals from 52.7% 
before polyI/polyC injection to 25.9% (10-13 weeks), to 19.8% (17-20 weeks) (Figures 
4.19A and 4.19B).  The chimerism of PBS-treated N51-FLT3-Cre+ animals however 
remained relatively constant around 40-45% donor cells over the same time frame.  We 
noticed significant variation in the PBS-treated animals, likely due to breakthrough Cre 
expression in some animals; therefore we present the data in bar graph form (Figure 
4.19A) as well as in scatter plots to demonstrate this variability (Figure 4.19B).  
Examining the EGFP percentages over time, again there was a significant decrease in the 
percent EGFP+ cells after polyI/polyC treatment of the N51-FLT3-Cre+ transplanted 
animals (Figures 4.20A and 4.20B) from 21.3% EGFP+ at baseline (before polyI/polyC 
treatment), to a mere 2.4% (10-13 weeks), to 1.9% EGFP+ (17-20 weeks).  Similar to the 
chimerism, the EGFP expression of PBS-treated N51-FLT3-Cre+ animals remains 
relatively constant at approximately 20% after PBS treatment with a slight dip in EGFP 
expression between weeks 10-13 (11.7%).  Again to demonstrate the variability between 
the PBS-treated animals the data is presented in bar graphs (Figure 4.20A) and in scatter 
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plots (Figure 4.20B).  These data suggest that after Shp2 is knocked out in the bone 
marrow of the polyI/polyC-treated N51-FLT3-Cre+ transplanted animals, the 
transplanted cells have a significantly reduced capacity to repopulate the recipient host.  
Furthermore, while chimerism is significantly lower, the EGFP expression is reduced to 
even lower percentages, suggesting that the remaining CD45.2+ donor cells have silenced 
N51-FLT3. 
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Figure 4.19:  Chimerism of polyI/polyC-treated vs. PBS-treated N51-FLT3, 
Shp2flox/flox;Mx1-Cre+ transplants 
 
(A) Chimerism (percent CD45.2+) shown as a bar graph displayed as the average 
chimerism at baseline (4 weeks post-transplant prior to polyI/polyC treatment), 10-13, 
and 17-20 weeks post-transplant +/- the standard error of the mean.  (B)  Chimerism 
(percent CD45.2+) shown as a scatter plot with the average at baseline (4 weeks post-
transplant prior to polyI/polyC treatment), 10-13, and 17-20 weeks post-transplant.  
Statistics generated using unpaired, two-tailed, student’s t test.  
A. 
B. 
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Figure 4.20:  EGFP levels of polyI/polyC-treated vs. PBS-treated N51-FLT3, 
Shp2flox/floxMx1-Cre+ transplants 
 
(A) EGFP+ shown as a bar graph displayed as the average at baseline (4 weeks post-
transplant prior to polyI/polyC treatment), 10-13, and 17-20 weeks post-transplant +/- the 
standard error of the mean.  (B)  EGFP+ shown as a scatter plot with the average at 
baseline (4 weeks post-transplant prior to polyI/polyC treatment), 10-13, and 17-20 
weeks post-transplant.  Statistics generated using unpaired, two-tailed, student’s t test.   
A. 
B. 
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In addition to percent chimerism and percent EGFP, we have also used the 
percent chimerism to calculate the hematopoietic stem cell (HSC) repopulating units 
(RU).  This is important because when we transplant mixtures of cells, it can be difficult 
to interpret differences in raw percentages.  Converting the data into repopulating allows 
us to calculate the actual differences in the numbers of long term engrafted stem cells in 
the recipient animals.  Repopulating units are calculated by dividing the percent donor 
cells by 100 minus percent donor cells and multiplying by the number of competitors X 
105.  The formula is shown below: 
 RU = Competitors (1 x 105) X % donor   
     100 - %donor  
 
An example: RU =   1.5 (we used 1.5 x 105 splenocytes) X 45% 
     55% 
 
 RU =  1.23 
 
 
Repopulating units calculated from mice 4-6 months after transplant represent the long-
term hematopoietic stem cells (HSCs).  The repopulating units of polyI/polyC-treated 
N51-FLT3-Cre+ transplanted animals was 1.5 prior to polyI/polyC treatment and 
decreased significantly to 0.4 by the 10-13 week time point as demonstrated in bar a bar 
graph (Figure 4.21A) and in a scatter plot to demonstrate animal-variability (Figure 
4.21B).  This reduction was maintained to the 17-20 week time point, also having 0.4 
repopulating units.  On the contrary, the repopulating units of PBS-treated N51-FLT3-
Cre+ transplanted animals started at 1.2 and increased significantly to 2.1 by the 17-20 
week time point.  There is a statistically significant difference at the latest time point (17-
20 weeks) which represents a higher stem cell function in the PBS-treated N51-FLT3- 
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Figure 4.21:  Average repopulating units of N51-FLT3, Shp2flox/floxMx1-Cre+ 
animals 
 
(A) Repopulating units (RU) shown as a bar graph displayed as the average at baseline (4 
weeks post-transplant prior to polyI/polyC treatment), 10-13, and 17-20 weeks post-
transplant +/- the standard error of the mean.  (B)  Repopulating units (RU) shown as a 
scatter plot with the average at baseline (4 weeks post-transplant prior to polyI/polyC 
treatment), 10-13, and 17-20 weeks post-transplant.  Statistics generated using unpaired, 
two-tailed, student’s t test.  
A. 
B. 
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Cre+ transplanted animals than in the polyI/polyC-treated N51-FLT3-Cre+ transplanted 
animals.   
Overall, these findings demonstrate that polyI/polyC-treatment to reduce Shp2 
expression significantly decreases the chimerism, EGFP expression, and repopulating 
units, or stem cell function of N51-FLT3-Cre+ transplanted animals. Importantly, these 
findings indicate that even in the presence of N51-FLT3, Shp2 is required for stem cell 
function and sustained hematopoiesis.  Furthermore, these data suggest that lack of Shp2 
expression confers a functional defect to the ability of hematopoietic stem cells to 
repopulate the recipient host, even when expressing oncogenic N51-FLT3, and indicate 
that the increased latency to and attenuated severity of the malignancy in the 
polyI/polyC-treated animals is due to a reduced competitive advantage of the N51-FLT3 
cells lacking Shp2 expression, leading to reduced repopulating activity and reduced 
establishment of malignancy.   
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N51-FLT3 transplants are more sensitive to loss of Shp2 than WT-FLT3 transplant 
recipient 
Given that loss of Shp2 results in reduced HSC/hematopoietic progenitor 
function, and self-renewal (Chan, Johnson et al. 2003; Chan, Li et al. 2006; Chan, 
Cheung et al. 2011; Zhu, Ji et al. 2011), and given that expression of FLT3-ITD, or 
constitutive active STAT5 in CD34+ HSCs results in enhanced self-renewal (Schuringa, 
Chung et al. 2004; Chung, Morrone et al. 2005), we were surprised to observe the early 
and profound bone marrow failure in the polyI/polyC-treated mice transplanted with 
N51-FLT3-Cre+ transduced cells.  This led us to hypothesize that the N51-FLT3-
transduced cells were particularly sensitive to loss of Shp2 expression.  To examine this 
hypothesis, we directly compared the repopulating ability of polyI/polyC-treated mice 
transplanted Shp2flox/flox ;Mx1Cre+ cells transduced with WT-FLT3 to that of N51-FLT3.  
We expected one of two outcomes.  Either the loss of Shp2 would result in bone marrow 
failure-induced death equally between polyI/polyC-treated WT-FLT3, 
Shp2flox/flox;Mx1Cre+ and polyI/polyC-treated N51-FLT3, Shp2flox/flox;Mx1Cre+ 
transplanted animals or that polyI/polyC-treated WT-FLT3, Shp2flox/flox;Mx1Cre+  
transplanted animals would be less susceptible to the loss of Shp2, suggesting that N51-
FLT3 is particularly sensitive to loss of Shp2. 
We compared the overall survival of polyI/polyC-treated animals transplanted 
with WT-FLT3-transduced Shp2flox/flox;Mx1Cre+ cells to polyI/polyC-treated animals 
transplanted with N51-FLT3-transduced Shp2flox/flox;Mx1Cre+ cells (Figure 4.22).  
Generally, the polyI/polyC-treated Cre+ WT-FLT3 transplanted mice had an increased 
survival compared to the polyI/polyC-treated Cre+ N51-FLT3 animals.  While there was 
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one early death (6 weeks post-treatment) in the polyI/polyC-treated Cre+ WT-FLT3 
transplanted animals, this death was not due bone marrow failure or malignancy, as 
determined by pathology.  In contrast, in the polyI/polyC-treated Cre+ N51-FLT3 
transplanted animals, the first two deaths (9 and 11 weeks post-treatment) were caused by 
bone marrow failure, while other animals lived significantly longer but did eventually 
succumb to malignancy.  Although these are preliminary findings, our data suggest that 
the N51-FLT3 transplanted animals are more dependent on Shp2 than their WT-FLT3 
transplanted counterparts, implying that there is an inherent difference between WT-
FLT3 and N51-FLT3 and that N51-FLT3 requires certain levels or functions of Shp2 that 
are not essential to WT-FLT3.   
108 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22:  Overall survival of polyI/polyC-treated animals transplanted with 
WT-FLT3- vs. N51-FLT3-transduced Shp2flox/flox;Mx1Cre+ cells 
 
Kaplan-Meier analysis of polyI/polyC-treated animals transplanted with WT-FLT3- vs. 
N51-FLT3-transduced Shp2flox/flox ;Mx1-Cre+ cells; n = 7 in each group.   
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To investigate the potential differences between the HSC compartments in 
polyI/polyC-treated animals transplanted with WT-FLT3- vs. N51-FLT3-transduced 
Shp2flox/flox;Mx1Cre+ cells we next examined average EGFP+ populations, average 
chimerism, and average repopulating units as shown in Figures 4.23, 4.24, and 4.25, 
respectively.  Interestingly, at baseline, EGFP expression was stronger in the N51-FLT3-
transplanted animals compared to the WT-FLT3-transplanted animals.  While EGFP 
populations decreased over time in both polyI/polyC-treated Cre+ WT-FLT3 transplanted 
animals as well as in polyI/polyC-treated Cre+ N51-FLT3 transplanted animals, the 
reduction from baseline in the N51-FLT3-transplanted animals was more substantial than 
in the WT-FLT3-transplanted animals and dropped to nearly zero by 24 weeks post-
treatment (Figure 4.23).   
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Figure 4.23:  Percent EGFP positive populations of polyI/polyC-treated WT-FLT3 
vs. polyI/polyC-treated N51-FLT3 transplant recipients 
 
Percent EGFP+ populations are shown as the average at each time point, baseline (4 
weeks post-transplant; right before polyI/polyC treatment), 13 weeks, and 24 weeks post-
transplant.  n = 7 in each group, statistics performed using unpaired, two-tailed student’s t 
test.   
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Comparing the chimerism of the two groups, the average chimerism of 
polyI/polyC-treated Cre+ WT-FLT3 transplanted animals displayed a minor decrease 
after polyI/polyC treatment (between baseline and 13 weeks), but then remained constant 
to the 24 week time point (Figure 4.24).  The chimerism of polyI/polyC-treated Cre+ 
N51-FLT3 transplanted animals, however, decreased sharply after polyI/polyC-treatment 
(between baseline and 13 weeks) and chimerism continued to decrease to significantly 
lower levels than the polyI/polyC-treated Cre+ WT-FLT3 transplanted animals by 24 
weeks post-transplant (Figure 4.24).   
We next converted chimerism to repopulating units (RU) and observed a trend 
toward increased RU in the N51-FLT3-transplanted animals at baseline compared to the 
WT-FLT3-transplanted animals.  However, similar to that observed with EGFP 
expression, the RU of the N51-FLT3-transplanted animals dropped drastically after 
polyI/polyC-treatment (baseline to 13 weeks) and continued to drop to significantly lower 
levels than the WT-FLT3-transplanted animals by 24 weeks post-treatment (Figure 4.25). 
Again, although this is a preliminary study with few animals, these data support 
our second hypothesis that there is an inherent difference between WT-FLT3 and N51-
FLT3 transplant recipients in the absence of Shp2.  WT-FLT3 transplants have a greater 
capacity to tolerate the loss of Shp2, whereas N51-FLT3 recipient animals depend on 
Shp2 to a greater extent, which is evident by the significant difference in survival, percent 
EGFP+, percent chimerism, and repopulating units when Shp2 is knocked out of the bone 
marrow of animals transplanted with N51-FLT3 compared to animals transplanted with 
WT-FLT3.  Overall, this suggests that while Shp2 is inherently important for normal 
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hematopoiesis and engraftment, in the presence of oncogenic N51-FLT3, Shp2 is even 
more important for stem cell function and hematopoiesis.   
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Figure 4.24:  Chimerism of polyI/polyC-treated WT-FLT3 vs. polyI/polyC-treated 
N51-FLT3 transplant recipients 
 
Chimerism (%CD45.2 positive populations) is shown as the average at each time point, 
baseline (4 weeks post-transplant, before polyI/polyC treatment), 13 weeks, and 24 weeks 
post-transplant.  n = 7 in each group; statistics performed using unpaired, two-tailed 
student’s t test.  
 
 
 
 
 
 
 
 
 
Figure 4.25:  Repopulating units of polyI/polyC-treated WT-FLT3 vs. polyI/polyC-
treated N51-FLT3 transplant recipients 
 
Repopulating unites are calculated by the formula (competitors x 105) x (%45.2/[100-
%45.2]) and are represented as the average at each time point; baseline (4 weeks post-
transplant, before polyI/polyC treatment), 13 weeks, and 24 weeks post-transplant. n = 7 
in each group, statistics performed using unpaired, two-tailed student’s t test.   
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Conclusions 
 
 Internal tandem duplication mutations within FLT3 have been a popular focus of 
AML researchers over the past several years; however, the molecular mechanisms of 
FLT3-ITDs are still unclear.  Our previous data demonstrate that in FLT3-ITD signaling 
there is constitutive association of Shp2 to the mutant FLT3-ITD receptor.  We have 
further demonstrated that genetic disruption of Shp2 in vitro results in reduced N51-
FLT3-induced cellular hyperproliferation and hyperactivation of STAT5, supporting the 
data presented in chapter 3 using Baf3 cell lines expressing WT-FLT3, N51-FLT3, or 
N73-FLT3 and shRNAs targeted to Shp2.   
 All of this in vitro data established and validated the rationale for proceeding into 
the Shp2 knock-out mouse model.  Our two main conclusions from these in vivo studies 
are the following.  First, without Shp2 expression, N51-FLT3-transduced cells induce 
malignancy in vivo with an increased latency and reduced severity compared to N51-
FLT3-transduced cells expressing wildtype levels of Shp2.  Second, preliminary studies 
suggested that N51-FLT3-transduced cells are more dependent on Shp2 for engraftment 
and stem cell function than WT-FLT3-transduced cells.  These findings suggest that cells 
expressing FLT3-ITD are particularly dependent on Shp2 at the stem cell level, which is 
relevant since AML is a clonal disease of aberrant hematopoietic stem cells.  However, 
even though the polyI/polyC-treated Cre+ N51-FLT3 transplanted animals had an 
increase in disease latency, they did eventually succumb to malignancy.  While targeting 
Shp2 may be beneficial in treating FLT3-ITD-positive AML patients, it will likely not be 
sufficient to cure them of disease.  Inhibition of Shp2 however, could be used in 
combination therapy as one target in a cocktail of drugs.  It would be interesting to 
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combine Shp2 inhibition with some of the FLT3 inhibitors, which also are insufficient to 
cure FLT3-ITD-positive AML as a monotherapy.   
 The Shp2flox/flox;Mx1Cre mouse model is quite challenging to work with because 
once Shp2 is knocked out, the knock out cells are difficult to culture long term.  In our 
experience, we have transduced them, sorted them, and then used them in experiments 
short term, but we must always be very conscious of the Shp2 levels when we are taking 
our final reading for each individual experiment.  As an alternative approach, it would be 
interesting to cross the Shp2flox/flox animals to a Vav-Cre transgenic mouse model 
(Georgiades, Ogilvy et al. 2002).  Vav-Cre is expressed in most hematopoietic cells of all 
hematopoietic organs (Georgiades, Ogilvy et al. 2002). Since the Vav promoter is not 
conditionally inducible, when it is endogenously activated, cre recombinase expression 
will result in recombination of the Shp2 gene and turn “off” its expression.  This model 
may be useful to maintain Shp2 “knocked out” in bone marrow cells; however, since the 
Vav promoter is activated fairly early in development, it is also possible that the 
Shp2flox/flox;VavCre animals may die in utero, as constitutional Shp2 knock out is 
embryonic lethal.  However, if the animals did mature to birth, or even to gestational day 
14.5 when fetal liver cells could be obtained, it may provide a complementary model to 
study the role of Shp2 in the presence of N51-FLT3 in an in vitro system.  Another 
possible experimental idea is to use the FLT3-ITD knock-in mouse model (now available 
from Jackson Laboratories) originally developed in Dr. Gary Gilliland’s lab (Lee, 
Tothova et al. 2007).  It would be interesting to cross the Shp2flox/flox mouse with the 
FLT3-ITD knock-in model to use as another mouse model to test the role of Shp2 on 
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FLT3-ITD-induced MPD by using the bone marrow cells in vitro or the animal models in 
vivo.   
 While our findings suggest that Shp2 is necessary for engraftment and stem cell 
function, we still have several in vivo options to consider.  Due to the high percentage of 
polyI/polyC-treated Cre+ N51-FLT3 transplanted animals that succumb to bone marrow 
failure, we have considered a few alternative approaches.  First, we could use bone 
marrow LDMNCs as supporting cells, as opposed to the splenocytes we have used in the 
past.  This experimental modification may be sufficient to supplement the bone marrow 
just enough to prevent bone marrow-induced death upon the deletion of Shp2 in the 
presence of N51-FLT3.  Another possibility is to use heterozygous Shp2flox/+;Mx1Cre+ 
animals as donor animals.  Therefore, after transduction of N51-FLT3, transplantation 
into lethally irradiated recipients, and treatment with polyI/polyC, recipient animals will 
only lose 50% of Shp2 in the N51-FL3-transduced cells.  We would hypothesize that this 
partial loss of Shp2 would be insufficient to cause bone marrow failure and death, yet 
sufficient to increase the latency to N51-FLT3-induced malignancy which would support 
further investigation of targeting Shp2 as one therapeutic option for FLT3-ITD-positive 
AML patients.    
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CHAPTER FIVE 
PROTEIN TYROSINE PHOSPHATASE, SHP2, INHIBITOR, II-B08;  
A POTENTIAL THERAPEUTIC OF FLT3-ITD-POSITIVE AML 
Introduction 
Current therapies for treating FLT3-ITD-poisitve AML focus on high dose 
chemotherapy.  However, these regimes are too harsh for the majority of AML patients.  
Those AML patients who are able to sustain such treatments still only have an 
approximate long term survival rate of 20%.  These poor survival rates offer a vast 
opportunity to identify specific molecular targets in an effort to develop better therapies 
for the treatment of AML.   
We presented solid functional evidence demonstrating that Shp2 contributes to the 
cellular hyperproliferation and hyperactivation of STAT5 in FLT3-ITD-expressing cell 
lines and murine primary cells.  Therefore, we were next interested in identifying a 
specific and efficacious Shp2 inhibitor.  Genetic approaches are highly informative for 
targeting specific genes and their respective proteins, and for understanding molecular 
mechanisms.  However, identifying a pharmacologic Shp2 inhibitor is a key step in 
actually treating FLT3-ITD-positive AML patients.  Fortunately, we were able to 
collaborate with tyrosine phosphatase biochemist, Dr. Zhong-Yin Zhang at the Indiana 
University School of Medicine.  He and his lab identified a novel, salicylic acid-based 
small molecule inhibitor which is both selective and potent in targeting the phosphatase 
domain of Shp2 called Compound 9 or II-B08 (Zhang, He et al.). Through this 
collaboration, we were able to use II-B08 to determine its effect on FLT3-ITD-positive 
primary cells in vitro.  We hypothesized that treating N51-FLT3-expressing primary 
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murine bone marrow cells with II-B08 would result in reduced hyperproliferation and 
hyperactivation of STAT5 compared to DMSO vehicle treatment.       
In addition to in vitro assays, we also tested II-B08 in vivo by taking advantage of 
a syngeneic transplant system.  32D cells are an IL-3-dependent, murine cell line derived 
fromC3h/HeJ mice which can be syngeneicly transplanted into C3h/HeJ recipient mice 
without the complications of irradiation.  Therefore, C3h/HeJ recipient mice were 
transplanted with N51-FLT3-expressing 32D cells in order to create a leukemic mouse 
model which could be subsequently treated with Shp2 inhibitor, II-B08, in order to 
evaluate its therapeutic potential.  We hypothesized that treating N51-FLT3-syngeneic 
transplant recipient animals with II-B08 would reduce N51-FLT3-induced elevated white 
blood cell counts, reduce N51-FLT3 (GFP) expression, and potentially improve the 
survival of these animals when compared N51-FLT3 syngeneic transplants treated with 
DMSO.   
 
Results 
 
Identification of Shp2 inhibitor, II-B08 
As identified in the publication, the chemical structure of II-B08 is shown in 
Figure 5.1A.  II-B08 is highly potent and selective for Shp2 with an IC50 value of 5.5 µM.  
In addition to its chemical structure, the ribbon structure is shown in Figure 5.1B, which 
demonstrates the orientation of II-B08 into the phosphatase domain of Shp2.  Compared 
to similar phosphatases, including, SHP1, PTP1B, and HePTP, II-B08 had an 
approximate 3-fold or better IC50 value as shown in Table 5.1 (adapted from (Zhang, He 
et al.)).  During our collaboration with Dr. Zhong-Yin Zhang, we also demonstrated that 
increasing concentrations of II-B08 resulted in decreased Erk activation and decreased 
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thymidine incorporation of cells expressing Shp2 gain-of-function mutations (Figures 4 
and 5 from (Zhang, He et al.) in which I am a co-author).  Using II-B08, we are also able 
to pharmacologically interrogate the contribution of Shp2 in FLT3-ITD-expressing cells. 
120 
 
 
 
 
Figure 5.1:  The Shp2 inhibitor, II-B08 
 
(A) Chemical structure of II-B08 (Compound 9).  (B) Ribbon diagram of Shp2 catalytic 
domain in complex II-B08.  The molecule is oriented with the C-terminal end of the β8 
strand toward the viewer.  α-Helices and β-strands are colored in red and yellow, 
respectively.  The P-loop is shown in green and the WPD loop in blue.  II-B08 is shown 
in stick-and-bond mode.  Figure adapted from (Zhang, He et al.). 
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Table 5.1:  Selectivity of II-B08 against a panel of protein tyrosine phosphatases 
(Adapted from (Zhang, He et al.)) 
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Shp2 inhibitor, II-B08, significantly reduces FLT3-ITD-induced hyperproliferation 
and activation of STAT5 
 We hypothesized that hyperproliferation induced by FLT3-ITDs would be 
significantly reduced by treatment with II-B08.  Furthermore, based on our previous 
biochemical and genetic studies, we hypothesized that N51-FLT3-expressing cells would 
be more sensitive to Shp2 inhibition compared to WT-FLT3-expressing cells.  
Proliferation assays were performed using thymidine incorporation assays (previously 
described).  EGFP-positive WT-FLT3- or N51-FLT3-expressing LDMNCs were starved 
for 4-5 hours and then plated into thymidine incorporation assays with increasing 
concentrations of II-B08.  We observed a dose-dependent, but statistically insignificant 
decrease in the proliferation of WT-FLT3-expressing cells upon II-B08 treatment (Figure 
5.2A).  However, N51-FLT3-expressing LDMNCs exhibited a statistically significant, 
dose-dependent decrease in the hyperproliferation induced by N51-FLT3 with increasing 
concentrations of II-B08 (Figure 5.2A).  This suggests that Shp2 inhibition has a greater 
effect on N51-FLT3-expressing cells than on WT-FLT3-expressing cells, which is very 
important in identifying a drug as a potential therapeutic.   
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Figure 5.2:  II-B08 treatment reduces cellular hyperproliferation induced by N51-
FLT3 
 
(A) Thymidine incorporation analysis of bone marrow LDMNCs transduced with either 
MSCV-WT-FLT3 or MSCV-N51-FLT3 in the absence or presence of increasing 
concentrations of II-B08; data is representative of two independent experiments 
combined with n = 4-6 replicates per experiment, *p=0.002 for N51-FLT3, 5µM II-B08 
v. N51-FLT1, baseline, **p<0.0001 for N51-FLT3, 10µM, 15µM, and 20µM II-B08 v. 
N51-FLT3, baseline (unpaired, two-tailed t-test).  (B) Immunoblot analysis of cells 
transduced with WT-FLT3 or N51-FLT3 and treated with or without 15µM II-B08 in the 
absence or presence of FL stimulation.  Blots were probed for phospho- and total- 
STAT5, phospho- and total-Shp2, phospho- and total-AKT, phospho- and total-Erk, and 
FLT3 protein levels. 
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To investigate the effect of II-B08 on the activation of STAT5, we treated sorted, 
bone marrow LDMNCs transduced with WT-FLT3 or N51-FLT3 with or without 15µM 
II-B08, and collected total cell lysates at baseline or after 5 minute stimulation 
with100ng/ml FL.  Total cell lysates were subjected to immunoblot analysis and probed 
for phospho- and total-STAT5, phospho- and total-Shp2, phospho- and total-AKT, 
phospho- and total-Erk, and FLT3 (Figure 5.2B).  While we do not detect any activation 
of STAT5 in the WT-FLT3 expressing cells regardless of FL-stimulation or II-B08 
treatment, there is a robust activation of STAT5 in the N51-FLT3-expressing cells at 
baseline and upon FL-stimulation.  This activation is abrogated by at least 50% when 
N51-FLT3-expressing cells are treated with II-B08 (Figure 5.2B).  The reduction in 
phospho-STAT5 in II-B08-treated, N51-FLT3 transduced cells is comparable to the 
reduction exhibited in phospho-Shp2 levels of II-B08 treated N51-FLT3 transduced cells 
(Figure 5.2B).  Upon examination of AKT, we similarly observed a reduction in AKT 
activation in II-B08-treated N51-FLT3-expressing cells upon FL-stimulation.  
Surprisingly, Erk activation was unaffected by II-B08 at this 5 minute time point.  
Collectively, however, this data suggests that pharmacologic inhibition of Shp2 using II-
B08 reduces cellular hyperproliferation, Shp2 hyperphosphorylation, and promiscuous 
activation of STAT5 induced by N51-FLT3. 
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II-B08 treatment reduces sustained Ras activation in N51-FT3-expressing cells   
 It has been well established that Shp2 activates Ras (Feng 1999); therefore we 
hypothesized that in the presence of FLT3-ITD mutants and a constitutive association of 
Shp2 to FLT3-ITD, there would subsequently be an increase in Ras activation.  As we 
were surprised to see a lack of effect of II-B08 on phospho-Erk levels in the N51-FLT3-
expressing cells, we directly examined FL-stimulated Ras activation in the presence of II-
B08.  Briefly, cells were starved in 0.2% BSA-IMDM for 4 hours and then treated with 
the indicated concentration of II-B08, or the maximum equivalent concentration of 
DMSO for 2 hours, with the indicated period of FL-stimulation (in the presence of II-
B08).  Cells were immediately lysed, protein extracts were quantified, and subjected to 
Ras activation assays.  Ras was constitutively activated in the N51-FLT3-expressing cells 
compared to the WT-FLT3-expressing cells; however, upon 5 minutes of FL-stimulation, 
similar to that observed with Erk activation, there was no detectable change in Ras 
activation in N51-FLT3- or WT-FLT3-expressing cells (Figure 5.3A).  As Shp2 has been 
shown previously to be critical for sustained activation of the Ras-Erk signaling cascade 
(Maroun, Naujokas et al. 2000; Shi, Yu et al. 2000), we next examined the effect of II-
B08 on Ras-GTP levels following 60 minutes of FL stimulation (Figure 5.3B).  Ras-GTP 
levels were reduced to nearly undetectable levels in the WT-FLT3-expressing cells 
following 60 minutes FL stimulation, while they remained elevated in the N51-FLT3 
expressing cells.  Treatment with II-B08 both at 10 and 20 µM significantly reduced FL-
stimulated Ras-GTP levels in the N51-FLT3-expressing cells (Figure 5.3B).  These 
findings indicate that reduced proliferation of the N51-FLT3-expressing cells by 
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treatment of II-B08 is mediated not only by reduced STAT5 activation but is also due to 
reduced Shp2 phosphorylation, Akt activation, and Ras activation.   
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Figure 5.3:  II-B08 treatment reduces sustained Ras activation in N51-FLT3-
expressing cells 
 
Ras activation assays with sorted, GFP+, WT-FLT3- or N51-FLT3-expressing LDMNCs.  
Cells were starved for 4 hours and then treated for 2 hours in the indicated concentration 
of II-B08, or DMSO vehicle with the last 5 (A) or 60 (B) minutes of 2-hour treatment in 
the presence of 100ng/ml FL.  Treated cells were then lysed, subjected to Ras activation 
assays, and analyzed by immunoblot analysis.  A small amount of total cell lysates were 
kept separate from the Ras activation assay and subjected directly to immunoblot with α-
Ras as a control (A and B).  
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II-B08 treatment increases apoptosis in N51-FLT3-expressing cells  
We have demonstrated that N51-FLT3 expressing cells treated with II-B08 have 
reduced hyperproliferation.  We next examined how II-B08 treatment affected apoptosis 
of N51-FLT3-expressing cells.  To address this question, sorted, GFP+, bone marrow 
LDMNCs transduced with either MSCV-WT-FLT3 or MSCV-N51-FLT3 were plated 
into 12-well non tissue culture plates in a total volume of 750µl of 2% FBS-IMDM or in 
the presence of DMSO, 5µM, 15µM, or 30µM II-B08 overnight at 37˚C.  Cells were 
collected and stained with propidium iodide and Annexin-V-APC and subjected to flow 
cytometry analysis.  Propidium iodide-single positive cells are necrotic, annexin-V-APC-
single positive cells are considered early apoptotic and double positive cells are in a state 
of late apoptosis.  Figure 5.4 represents the percent increase in apoptosis detected when 
the II-B08-treated samples were compared to the average apoptosis in DMSO treated 
cells.  Upon treatment with low levels of II-B08, WT-FLT3 and N51-FLT3-expressing 
cells have a similar level of apoptosis (Figure 5.4).  However, when cells are treated with 
30 µM II-B08, there is a dramatic, statistically significant increase in the apoptosis of 
N51-FLT3-expressing cells compared to WT-FLT3-expressing cells (Figure 5.4).  In fact 
as the concentration of II-B08 increases there is a statistically significant, dose dependent 
increase in the percent apoptotic cells in N51-FLT3-expressing cells which is not 
exhibited in WT-FLT3-expressing cells.   
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Figure 5.4: Apoptosis induced by II-B08 
 
Annexin-V staining, measuring apoptosis of WT-FLT3 or N51-FLT3 transduced cells.  
Apoptosis is shown as percent increase in annexin-V staining when cells were treated 
with 5µM, 15µM, or 30µM II-B08 and compared to DMSO.  n = 4.  P = 0.002 for 5µM 
II-B08 WT-FLT3 v. N51-FLT3; P < 0.01 for 5µM II-B08 N51-FLT3 v. 15µM II-B08 
N51-FLT3 and for 15µM II-B08 N51-FLT3 v. 30µM II-B08 N51-FLT3 as determined by 
unpaired, two-tailed, t-test. 
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This data demonstrates that N51-FLT3-expressing cells are more sensitive to the 
inhibition of Shp2 compared to WT-FLT3-expressing cells and this sensitivity is 
exhibited by a robust increase in the percent apoptotic cells in N51-FLT3-expressing cells 
treated with moderate amounts of II-B08. The increase in apoptosis in N51-FLT3 cells, 
but not in WT-FLT3 cells, supports the use of II-B08 in further investigation including in 
vivo models and as a potential therapeutic agent for FLT3-ITD-positive AML.   
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Syngeneic 32D-N51-FLT3 transplant recipients develop myeloproliferative disorder 
(MPD) and can be used to test II-B08 in vivo 
 In vitro assays using inhibitors are valuable because they help researchers 
understand the molecular mechanisms of pharmacologic inhibition.  However, in addition 
to the in vitro assays which have been described, we were interested in testing the effects 
of II-B08 in vivo.  Therefore, we utilized a syngeneic leukemic mouse model and 
subsequently treated the animals with II-B08.   
To create this mouse model, fellow graduate student, Charles Goodwin, and I 
collaborated to transduce nascent 32D cells with pMSCV-N51-FLT3-EGFP viral 
supernatant for two consecutive days.  Cells were then sorted on EGFP expression and 
the EGFP+ cells expanded.  After the cells had expanded sufficiently, EGFP expression 
was re-evaluated using flow cytometry demonstrating robust expression (96% EGFP 
positive, Figure 5.5).  C3h/HeJ recipient animals were transplanted with 2 X 106 32D-
N51-FLT3 cells via tail vein injection.  Three weeks after transplantation, peripheral 
blood was collected via tail vein and assessed by complete blood counts (cbc) as well as 
percent GFP+ cells as shown in Figure 5.5.  Animals demonstrated elevated EGFP 
expression were divided into two groups for treatment with either 100mg/kg of II-B08 or 
with an equivalent volume of 50% DMSO:PBS.   
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Figure 5.5:  Schematic representation of syngeneic transplant 
 
C3h/HeJ female recipients were transplanted with 2 X 106 32D-N51-FLT3 cells. Mice 
were monitored for white blood cell counts and EGFP expression by the collection of tail 
vein peripheral blood.  When mice exhibited an elevated EGFP level, they were then 
treated either with 100mg/kg II-B08 or the equivalent volume of vehicle and monitored 
over time.   
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Transplantation of N51-FLT3-expressing cells into lethally irradiated recipients 
has previously been shown to develop lethal myeloproliferative disorder with an average 
latency of 40 to 50 days (Kelly, Liu et al. 2002).  However in this syngeneic 32D-N51-
FLT3 transplant system, recipients succumbed to myeloproliferative disorder in 
approximately half of the recipients, with an average latency of 3-5 weeks.  The animals 
that developed MPD had rapidly increasing GFP percentages and white blood counts, 
with profound splenomegaly.  Figure 5.6 displays an example of one of 32D-N51-FLT3 
syngeneic recipient that succumbed to MPD.  The percent EGFP increased rapidly 
between weeks 3 and 5 (Figure 5.6A).  There was also marked splenomegaly displayed in 
the diseased animal (Figure 5.6B and 5.6C).  The 1.48gm spleen weighed nearly 10 times 
the average weight of a WT spleen and measured over 3cm in length (Figure 5.6C).  The 
development of MPD in these syngeneic 32D-N51-FLT3 transplant animals sets up the 
system as one which will be useful to test II-B08.   
To test II-B08 in vivo, 22 C3h/HeJ animals were transplanted with 2 X 106 32D-
N51-FLT3 cells as shown in Figure 5.5.  Of these, 7 animals developed high EGFP levels 
and were subsequently randomized for treatment with either II-B08 or vehicle.  Four 
animals were placed into the II-B08 treatment group and 3 in the DMSO group.  They 
were each treated with daily intraperitoneal injections of either 100mg/kg II-B08 or the 
equivalent volume of 50% DMSO:PBS for up to 20 days.  The combined survival data is 
shown by Kaplan Meier analysis (Figure 5.7).  While most animals rapidly succumb to 
MPD regardless of treatment group, there was one II-B08-treated animal (N125) that 
demonstrated long-term survival (Figure 5.7).   
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Figure 5.6:  N51-FLT3 induces MPD in a syngeneic transplant model 
 
(A) Representative 32D-N51-FLT3-transplanted animal displays EGFP expression of 
21.7% and 95.1% at 3 and 5 weeks post-transplant, respectively.  (B)  Splenomegaly and 
hepatomegaly are apparent after the animal died.  (C)  Spleen is over 3 cm long.      
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Figure 5.7:  Overall survival of animals with established N51-FLT3-induced MPD 
treated with II-B08 or vehicle 
 
Survival curve of animals treated with either 100mg/kg daily or the equivalent volume of 
50% DMSO:PBS.  Animals were started on the treatment when their peripheral blood 
draw displayed significant EGFP-positive expression (established disease).   
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Animal N125 demonstrated 15% positive EGFP at the initiation of II-B08 
therapy, and demonstrated a marked reduction in EGFP expression after 1 week of 
treatment with II-B08 (Figure 5.8A).  N125 was treated with II-B08 for a total of 20 days.  
The reduction of GFP+ expressing cells was sustained long-term, up to the last blood 
draw at 20 weeks post-transplant (Figure 5.8A).  Even after II-B08 treatment was 
terminated, animal N125 continued to live for another 4 months.  At the time of elective 
euthanasia, the spleen weight was moderately enlarged at 0.15g.  Upon examination of 
the histopathology, the spleen had fairly normal splenic architecture with well-defined 
red and white pulp (Figure 5.8B).  The femur, however, demonstrated many mitotic 
figures as well as an over-abundance of neutrophils, indicative of MPD (Figure 5.8C).  
The white blood cell count of N125, however, remained relatively low (7.58-13.64 
thousand wbc/ml), indicating indolent, rather than aggressive, disease.  While the 
description of this one animal’s response to II-B08 is anecdotal, it is possible that the 
15% EGFP+ population of cells was modest enough that II-B08 was able to effectively 
suppress the growth and expansion of the N51-FLT3-expressing cells and thus permit 
substantially increased survival.   
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Figure 5.8:  N51-FLT3 syngeneic transplant animal, N125, had increased life span 
after II-B08 treatment 
 
(A) EGFP+ expression of peripheral blood 7, 8, and 20 weeks post-transplant.  II-B08 
treatment started after the 7 week blood draw demonstrating 15% EGFP+ cells and 
continued for 20 days.  (B) H&E staining of the spleen was relatively normal, while the 
bone marrow (C) demonstrated leukemia.      
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Conclusions 
 
FLT3-ITDs have been a popular target of many researchers seeking to find better 
therapies for FLT3-ITD-positive AML.  Many FLT3 inhibitors have been tried and thus 
far FLT3-ITDs remain a difficult target rendering FLT3-ITD-positive AML patients 
challenging to treat with generally poor outcomes.  Therefore, we are particularly 
interested in testing the Shp2 inhibitor, II-B08, as we have demonstrated that using 
biochemical and genetic studies that Shp2 plays a role in FLT3-ITD-signaling.  In testing 
a pharmacologic inhibitor, there are several levels of interrogation.    
We demonstrated that N51-FLT3-expressing primary cells are more sensitive to 
II-B08 treatment than their WT-FLT3-expressing counterparts.  The hyperproliferation of 
N51-FLT3-expressing primary cells is significantly reduced in a dose-dependent manner 
when these cells are treated with increasing concentrations of II-B08.  The proliferation 
of WT-FLT3-expressing cells however, is slightly but not statistically significantly 
reduced with increasing concentrations of II-B08.  Biochemically II-B08 reduces 
hyperphosphorylation of STAT5 and Shp2 and of sustained Ras activation induced by 
N51-FLT3.  In addition, N51-FLT3-positive cells have a higher increase in II-B08-
induced apoptosis than WT-FLT3-positive cells.   
In vivo we have treated a small cohort of N51-FLT3-ITD-positive animals with II-
B08 who had begun to show signs of MPD.  While this study is very preliminary, we did 
observe one animal that had a long term survival as a result of II-B08 treatment, 
rendering II-B08, or future derivative drugs with higher potency and specificity for Shp2, 
as attractive pharmacologic agents as we consider future studies using Shp2 inhibitors in 
FLT3-ITD-induced leukemia.  Currently, Jackson Laboratories has FLT3-ITD knock-in 
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mice.  These animals would be an ideal alternative to the syngeneic transplant animals 
and could potentially be used for II-B08 treatment directly to test the efficiency of the 
Shp2 inhibitor. 
By defining targetable molecules in the FLT3-ITD-leukemogenic pathway, we 
can begin to uncover the options in finding better therapeutic targets which will lead to 
the development of better therapeutic options for the thousands of FLT3-ITD-positive 
AML patients desperately awaiting a cure.  While our data demonstrated a benefit of 
using II-B08 in vitro, the in vivo data is still too young to determine if II-B08 could have 
some therapeutic benefits.   
 It has been demonstrated that II-B08 binds the catalytic pocket of Shp2 blocking 
its phosphatase activity (Zhang, He et al.).  Just because II-B08 binds the catalytic site of 
Shp2 and has an effect on downstream signaling, does not necessarily imply that all 
Shp2-related functions are blocked.  The SH2 domains of Shp2 in particular are used to 
help Shp2 dock to other phosphorylated proteins and causes signaling cascades.  In 
prolactin signaling, the C-SH2 domain has been shown to be important in positively 
regulating STAT5 (Chughtai, Schimchowitsch et al. 2002).  Therefore, while we are able 
to exhibit a decrease in N51-FLT3-induced STAT5 activation by blocking the 
phosphatase activity of Shp2 with II-B08 treatment, it may be possible to further reduce 
STAT5 activation by also abrogating the C-SH2 domain of Shp2.   
We have demonstrated that Shp2 is an attractive target for treating FLT3-ITD-
positive AML patients.  While we have data which supports further investigation of II-
B08, it is highly likely that it will be insufficient in curing FLT3-ITD-positive AML in its 
entirety, but may be useful for combination therapy.  As we know, combination therapy 
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is becoming more prevalent and necessary to treat diseases with poor prognosis, therefore 
it may be beneficial to consider the inhibition of Shp2 for treating FLT3-ITD-positive 
AML. 
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CHAPTER SIX 
DISCUSSION 
Despite vigorous efforts to develop better treatments and therapies, the current 
treatment options for FLT3-ITD+ AML patients remain limited, especially in the elderly 
population where the disease is most prevalent.  To date, the survival rates of FLT3-ITD+ 
patients remain significantly lower than FLT3-ITD- AML patients (Abu-Duhier, 
Goodeve et al. 2000).  In order to better understand the molecular mechanisms 
contributing to FLT3-ITD-induced malignancy, we have investigated the role of Shp2 in 
FLT3-ITD-positive cell lines, primary cells, and in an in vivo mouse model.   
Using Baf3 cells expressing WT-FLT3, N51-FLT3, or N73-FLT3, we 
demonstrated that N51-FLT3 and N73-FLT3 induce cellular hyperproliferation (Figure 
3.1A), and hyperactivation of Stat5 (Figure 3.1C).  Furthermore, we found that Shp2 is 
constitutively associated to N51-FLT3 (Figure 3.2A) and N73-FLT3 (Figure 3.2B) in 
Baf3 cells as well as to FLT3-ITDs in human cells (Figure 3.3B).  Upon shRNA-targeted 
knock down of Shp2, we found a significant decrease in the hyperproliferation induced 
by N51-FLT3 (Figure 3.6C) and N73-FLT3 (Figure 3.6D).  Finally, our findings 
demonstrate that Shp2 immunoprecipitates with STAT5 (Figure 3.4) as well as co-
localizes with STAT5 in the nucleus of FLT3-ITD positive hematopoietic cells (Figure 
3.7).  Most novel, however, is the finding that Shp2 is found in a complex at the STAT5-
regulated promoter sequence of BCL2L1, which controls the transcription of the pro-
survival gene Bcl-XL (Figure 3.8B).  This mechanism is strikingly different than the well-
known role of Shp2 as a cytosolic signaling molecule and implies a novel function and 
mechanism of Shp2 in combination with STAT5 in FLT3-ITD positive AML.  These data 
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demonstrate that Shp2 plays an important role in FLT3-ITD-induced cellular 
proliferation, and that the implications extend beyond findings in transduced Baf3 cells, 
as we have also demonstrated that Shp2 is associated to FLT3-ITD in human cells 
expressing endogenous FLT3-ITD, supporting the general idea that Shp2 is important for 
FLT3-ITD-induced cellular transformation and leukemogenesis.   
Future experiments may include further investigation of the role of Shp2 in the 
nucleus of leukemic cells.  Since we exhibited Shp2 at the promoter sequence of STAT5 
target, Bcl-XL, it would be informative to see which (if any) other STAT5 transcriptional 
targets Shp2 may act on and/or if it is recruited to any other nuclear proteins.  We 
demonstrated that Shp2 and STAT5 form a complex at the promoter of STAT5 
transcriptional target, Bcl-XL, however we have yet to elucidate the full function of Shp2 
in the nucleus and/or which domain of Shp2 may be responsible for this interaction.  It is 
possible that Shp2 acts as a scaffolding protein within a larger transcriptional complex 
which also contains STAT5.  Alternatively, Shp2 may function to dephosphorylate an 
unknown protein substrate, permitting constitutive phosphorylation and activation of 
STAT5 at STAT5-responsive promoters.  To test the role of Shp2 on the activation of 
Bcl-XL, another possible experiment is to perform luciferase assays with luciferase 
expression linked to the Bcl-XL promoter sequence and express a dominant-negative form 
(either C-SH2, N-SH2, or phosphatase domain mutant) of Shp2 in MV411 cells, with the 
hypothesis that Bcl-XL-driven luciferase activity will decrease in the presence of 
dominant-negative Shp2 compared to wild type Shp2.  The use of Shp2-C-SH2-, N-SH2-, 
and phosphatase-domain mutants, will allow us to determine which of these three Shp2 
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domains is most important for the co-localization of Shp2 with STAT5 and with the 
activation of STAT5 target, Bcl-XL in FLT3-ITD-positive hematopoietic cells.   
Using primary murine bone marrow low density mononuclear cells (LDMNCs) 
transduced with WT-FLT3 or N51-FLT3, we were able to confirm the data generated in 
Baf3 cells, that N51-FLT3 induces hyperproliferation (Figure 4.1B) and hyperactivation 
of Stat5 (Figure 4.2) compared to WT-FLT3.  One of the biggest benefits of using 
primary cells is that, unlike heterologous cell lines, they are not transformed and, thus, 
are less likely to yield misleading experimental results.  That in mind, the primary cell 
experiments presented played a vital role in setting up the fundamental experimental 
model to progress and use the Shp2flox/flox;Mx1-Cre+ mouse model, which demonstrated 
that loss of physiologic Shp2 (polyI/polyC-treated Shp2flox/flox;Mx1-Cre+ LDMNCs) 
reduces N51-FLT3-induced hyperproliferation and hyperactivation of STAT5 in vitro 
(Figures 4.6-4.8). 
Given that Shp2 has been shown to interact with tyrosine 599 (Y599) of WT 
FLT3, some future experimental goals using primary cells include the modification of 
Y599 to phenylalanine (Y599F) in the first, second or both Y599 residues of N51-FLT3 
followed by transduction of the modified N51-FLT3-Y599F constructs into primary cells 
to determine which residue(s) is(are) most important for N51-FLT3-induced cellular 
hyperproliferation and activation of STAT5.  Furthermore, since the C-SH2 domain of 
Shp2 has been implicated in the phosphorylation of and association with STAT5 in 
mammary epithelial cells (Chughtai, Schimchowitsch et al. 2002), I would like to mutate 
the N-SH2, C-SH2, or phosphatase domains of Shp2 (all of these constructs have been 
made and are available in the Chan lab), co-transduce these mutant Shp2 constructs with 
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N51-FLT3 into primary cells, and use functional and biochemical assays to determine 
which domain of Shp2 is most important for proliferation and STAT5 constitutive 
activation.  Given that the C-SH2 domain of Shp2 has been implicated in the Shp2-
STAT5 interaction, I hypothesize that in the presence of N51-FLT3 and C-SH2 Shp2 
domain mutant, the mutant Shp2 would be unable to properly phosphorylate and/or 
associate with STAT5 and therefore result in reduced hyperproliferation and 
hyperactivation of STAT5 compared to cells co-expressing N51-FLT3 and wild type 
Shp2.  These experiments would be very informative in further understanding which 
domains of Shp2 are responsible for recruitment to Y599 of FLT3 as well as the 
promiscuous activation of STAT5.  A better understanding of the function of Shp2 in this 
model system would yield implications and potentially a paradigm for Shp2 function in a 
multitude of malignant diseases.     
 Using the in vivo model, we found that a loss of Shp2 in the bone marrow of N51-
FLT3 transplant recipients led to bone marrow failure and death in some recipients 
(Figures 4.15 and 4.16); however, those animals that did not succumb to bone marrow 
failure early-on did demonstrate a statistically significant increase in survival due to 
increased latency to malignancy, compared to N51-FLT3 transplant recipients with 
wildtype levels of Shp2 (Figure 4.18).  Furthermore, in one experiment directly 
comparing polyI/polyC-treated animals transplanted with Cre+N51-FLT3- v. Cre+ WT-
FLT3-transduced cells, animals transplanted with the Cre+N51-FLT3-transduced cells 
tended to be more sensitive to loss of Shp2 and succumb to bone marrow failure (2 of 7 
animals), whereas polyI/polyC-treated Cre+ WT-FLT3 transplant recipients did not (0 
out of 7 animals).  While these data (polyI/polyC-treated Cre+N51-FLT3 vs. 
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polyI/polyC-treated WT-FLT3) were generated with a small sample size, it does suggest 
that N51-FLT3 is more dependent on Shp2 than WT-FLT3 in transplant recipients, which 
implicates a fundamental difference in the signaling mechanisms in N51-FLT3 compared 
to WT-FLT3. 
 While these in vivo data are informative, and suggest that targeting Shp2 may be 
useful, it is likely not the hallmark cure for FLT3-ITD+ AML.  It has been well 
established that Shp2 is important in hematopoietic stem cells and normal hematopoiesis 
(Qu, Shi et al. 1997; Qu, Yu et al. 1998; Chan, Johnson et al. 2003; Chan, Li et al. 2006; 
Chan, Cheung et al. 2011; Zhu, Ji et al. 2011), nevertheless, we hypothesized that in the 
presence of N51-FLT3, loss of Shp2 could correct N51-FLT3-induced malignancy.  
While the loss of Shp2 increased the latency to N51-FLT3-induced leukemic phenotype, 
Shp2 is still essential for normal hematopoiesis, therefore it also caused bone marrow 
failure.  Targeting Shp2 in FLT3-ITD+ patients could be potentially beneficial, but the 
therapeutic window may be narrow.  Therefore, it is likely that targeting Shp2 will need 
to be carefully titrated in order to reduce Shp2 to a level that is low enough to diminish 
the penetration of N51-FLT3-induced transformation and be therapeutically beneficial, 
but to maintain an adequate Shp2 level to prevent bone marrow failure and subsequent 
death.   
 In targeting Shp2 pharmacologically with novel Shp2 inhibitor, II-B08, we were 
able to demonstrate that inhibition of the phosphatase activity of Shp2 in primary cells 
expressing N51-FLT3 results in a dose-dependent and statistically significant reduction in 
hyperproliferation with increasing concentrations of II-B08 (Figure 5.2A).  
Biochemically, we demonstrated that 15µM of II-B08 was sufficient to reduce the 
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promiscuous activation of STAT5, reduce phospho-Shp2, and phospho-Akt levels 
(Figure 5.2B).  The percent increase in apoptosis in cells expressing N51-FLT3 increases 
significantly in N51-FLT3-expressing cells upon increasing concentrations of II-B08, 
while this increase in apoptosis is not evident in WT-FLT3-expresssing cells (Figure 5.4).  
These functional and biochemical data suggested that Shp2 inhibition in vitro with II-B08 
successfully inhibited FLT3-ITD-induced hyperproliferation, leading us to test its 
potential efficacy in vivo.  
 Syngeneic N51-FLT3 transplant recipients succumb to FLT3-ITD-induced 
malignancy approximately 40% of the time.  Four out of seven of those leukemic mice 
were treated with 100mg/kg II-B08 by daily IP injection for up to 20 days.  While our 
subset of animals was limited, one of the animals had long-term survival (Figure 5.7) and 
went into a remission-like state as its peripheral blood percent EGFP population dropped 
from 15.6% (prior to II-B08 treatment) to 0.2% one week after starting treatment (Figure 
5.8).  This low EGFP percentage was maintained until the animal’s euthanasia 
approximately 4 months following II-B08 therapy.  While this finding is highly 
preliminary, it suggests further investigation and/or development of more specific and 
potent Shp2 inhibitors may improve the efficacy of Shp2 inhibition in vivo and improve 
its potential therapeutic benefits.     
 Taken together, our data demonstrate a novel role of Shp2 in a complex with 
STAT5 in the nucleus of FLT3-ITD-expressing cells.  Additionally, both of our in vivo 
studies (genetic knock out of Shp2 and pharmacologic Shp2 inhibition with II-B08) 
suggest that a controlled loss of Shp2 expression/function could provide a therapeutic 
benefit to FLT3-ITD-positive AML patients.  While much is known about Shp2 in 
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cancers, our current findings contribute significantly to the greater Shp2 research 
community, as they provide a novel Shp2 mechanism in myeloid malignancies and yield 
a potential novel therapeutic approach in FLT3-ITD+ AMLs.    
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Overall Conclusions and Significance 
 Internal tandem duplications in FLT3 (FLT3-ITDs) account for approximately 
30% of the mutations reported in AML patients, are associated with poor clinical 
prognosis, and the molecular mechanism of how they signal to induce leukemogenesis is 
poorly understood.  In the process to further understand their molecular mechanisms, we 
expected to observe that Shp2 is important for FLT3-ITD-induced proliferation, 
activation of STAT5, and the development and/or progression of N51-FLT3-induced 
MPD in vivo.  We further expected that loss or reduction of Shp2 expression and/or 
function would at least partially correct the cellular hyperproliferation, constitutive 
activation of STAT5, and either prevent the onset or increase the latency to N51-FLT3-
induced malignancy in vivo. 
 We discovered several novel findings regarding the molecular mechanisms of 
FLT3-ITD-induced malignancy.  While Shp2 is normally localized to the cytoplasm and 
functions as a cytosolic signaling molecule, in the presence of FLT3-ITD-activing 
mutations we demonstrated that Shp2 co-localizes with STAT5 in the nucleus, at the 
BCL2L1 promoter region which activates STAT5-responsive transcriptional target, Bcl-
XL.  To our knowledge, this is the first time Shp2 has been found at a STAT5 promoter in 
leukemic cells and suggests a novel role of Shp2 in the nucleus where it likely functions 
to drive transcription of pro-leukemic proteins.  This novel role of Shp2 as an important 
co-molecule in a complex with STAT5 at STAT5-responsive genes leads us to consider 
other potential gene response elements where Shp2 may function and/or other potential 
transcription factors Shp2 may cooperate with to promote pro-leukemic signals.  Future 
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investigation is needed to address these questions and to better understand the 
implications of the Shp2-STAT5 complex in the setting of leukemogenesis.   
 In addition to Bcl-XL, Stat5 also up-regulates cell cycle promoting gene, Cyclin-
D1, and the proto-oncogene, Pim-1, therefore it would be interesting to test for a similar 
Shp2-STAT5 complex at the promoter sequences of Cyclin-D1 and Pim-1 which would 
support our novel finding that Shp2 acts in cooperation with transcription factor STAT5 
in the nucleus.  STAT family member, Stat3 regulates cell cycle progression genes Fos, 
Cyclin-D, and c-Myc as well as anti-apoptotic genes BCL2 and Bcl-XL.  Data suggests 
that Shp2 gain-of-function mutations negatively regulate STAT3, and that Shp2 gain-of-
function mutations are associated with decreased binding between STAT3 and DNA 
(Zhang, Chan et al. 2009).  Therefore, it may be relevant to test nuclear co-localization of 
STAT3 and Shp2 in leukemic cells.   
 In vivo, we discovered that transplant of Shp2-deficient N51-FLT3-expressing 
cells results in increased latency and decreased severity of FLT3-ITD-induced 
malignancy which suggests that inhibiting Shp2 may have therapeutic benefit to FLT3-
ITD+ AML patients.  In addition, animals transplanted with N51-FLT3-expressing cells 
seemed to be much more sensitive to loss of Shp2, as they more commonly succumb to 
bone marrow failure and subsequent death compared to animals transplanted with WT-
FLT3-expressing cells.  This increased sensitivity of FLT3-ITD-expressing cells to loss 
of Shp2 implies that targeting Shp2 could be used as a therapeutic advantage to 
selectively target FLT3-ITD+ cells over WT cells.   
 Collectively we demonstrated a novel role of Shp2 in the nucleus at Stat5-
responsive gene elements and show convincing evidence that targeting Shp2 may provide 
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therapeutic benefit to treat FLT3-ITD-positive AML.  While these findings are vital to 
better understand the role of Shp2 in FLT3-ITD-induced leukemogenesis, they have a 
broader impact because mutations in Shp2 are present in about 50% of patients with the 
congenital disorder, Noonan Syndrome (NS), which have an increased susceptibility in 
the pediatric disease, juvenile myelomonocytic leukemia (JMML).  Although it is a rare 
disease, approximately 30% of JMML patients (who do not have NS) also have causative 
Shp2 mutations.  My studies demonstrate that FLT3-ITDs constitutively recruit Shp2 and 
result in increased Shp2 activity.  This increase in Shp2 activity could be paralleled with 
gain-of-function Shp2 mutations found in NS and JMML in the sense that both diseases 
have increased Shp2 function.  In addition to the role of Shp2 in leukemogenesis, further 
understanding of the molecular mechanisms of aberrantly activated Shp2 may have 
implications in other types of malignancies in which Shp2 has been implicated including 
breast, lung, and gastric cancers.  For example, Shp2 is essential for the transformation of 
breast cancer cells and inhibition of Shp2 reverts diseased tissue back to a normal breast 
epithelial phenotype (MET) (Zhou and Agazie 2008).  Also, suppression of Shp2 in lung 
cancer cell lines results in reduced proliferation and c-Myc expression which may suggest 
that Shp2 positively cooperates with STAT3 at STAT3 transcriptional target, c-Myc 
(Ren, Chen et al. 2010).  While these diseases are phenotypically distinct, greater 
understanding of the molecular mechanisms surrounding Shp2 could provide further 
insight into treating these diseases. 
As medical technologies advance, the implication and use of personalized 
medicine is becoming more essential and moving toward being the “new” standard of 
care.  It is currently a routine practice to receive molecular testing as part of a traditional 
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cancer work-up in order to dictate which cocktail of drugs and treatments will best attack 
one’s specific molecular aberrations.  This molecular diagnosis is even more specific than 
a general phenotypic diagnosis of AML, CML, breast cancer, or the like, and allows for 
much more targeted and specialized treatment.  While there are trends and common 
mutations within patients with the same disease, each patient has a unique set of 
molecular markers rendering them more or less likely to benefit from each particular 
therapy.  Therefore, a further understanding of the molecular mechanisms surrounding 
FLT3-ITDs and Shp2, including the multitude of diseases Shp2 has been implicated in is 
of the upmost importance as the field of personalized medicine advances.    
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